1 Novel risk loci for COVID-19 hospitalization among

2 admixed American populations

Silvia Diz-de Almeida,^{1,2,135} Raquel Cruz,^{1,2,135} Andre D. Luchessi,³ José M. Lorenzo-Salazar,⁴ 3 Miguel López de Heredia,² Inés Ouintela,⁵ Rafaela González-Montelongo,⁴ Vivian N. Silbiger,³ 4 Marta Sevilla Porras,^{2,6} Jair Antonio Tenorio Castaño,^{2,6,7} Julian Nevado,^{2,6,7} Jose María 5 Aguado,^{8,9,10,11} Carlos Aguilar,¹² Sergio Aguilera-Albesa,^{13,14} Virginia Almadana,¹⁵ Berta Almoguera,^{16,2} Nuria Alvarez,¹⁷ Álvaro Andreu-Bernabeu,^{18,10} Eunate Arana-Arri,^{19,20} Celso 6 7 Arango,^{18,21,10} María J. Arranz,²² Maria-Jesus Artiga,²³ Raúl C. Baptista-Rosas,^{24,25,26} María 8 Barreda- Sánchez,^{27,28} Moncef Belhassen-Garcia,^{29,30} Joao F. Bezerra,³¹ Marcos A.C. Bezerra,³² 9 Lucía Boix-Palop,³³ María Brion,^{34,35} Ramón Brugada,^{36,37,35,38} Matilde Bustos,³⁹ Enrique J. 10 Calderón,^{39,40,41} Cristina Carbonell,^{42,30} Luis Castano,^{19,43,2,44,45} Jose E. Castelao,⁴⁶ Rosa Conde-11 Vicente,⁴⁷ M. Lourdes Cordero-Lorenzana,⁴⁸ Jose L. Cortes-Sanchez,^{49,50}, Marta Corton,^{16,2} M. 12 Teresa Darnaude,⁵¹ Alba De Martino-Rodríguez,^{52,53} Victor del Campo-Pérez,⁵⁴ Aranzazu Diaz 13 de Bustamante,⁵¹ Elena Domínguez-Garrido,⁵⁵ Rocío Eirós,⁵⁶ María Carmen Fariñas,^{57,58,59} 14 María J. Fernandez-Nestosa⁶⁰ Uxía Fernández-Robelo,⁶¹ Amanda Fernández-Rodríguez,^{62,11} 15 Tania Fernández-Villa,^{63,41} Manuela Gago-Domínguez,^{5,64} Belén Gil-Fournier,⁶⁵ Javier Gómez-16 Arrue,^{52,53} Beatriz González Álvarez,^{52,53} Fernan Gonzalez Bernaldo de Quirós,⁶⁶ Anna 17 González-Neira,¹⁷ Javier González-Peñas,^{18,10,21} Juan F. Gutiérrez-Bautista,⁶⁷ María José 18 Herrero,^{68,69}Antonio Herrero-Gonzalez,⁷⁰ María A. Jimenez-Sousa,^{62,11} María Claudia Lattig,^{71,72} 19 Anabel Liger Borja,⁷³ Rosario Lopez-Rodriguez,^{16,2,74} Esther Mancebo,^{75,76} Caridad Martín-20 López,⁷³ Vicente Martín,^{63 41} Oscar Martinez-Nieto,^{77,72} Iciar Martinez-Lopez,^{78,79} Michel F. 21 Martinez-Resendez,⁴⁹ Ángel Martinez-Perez,⁸⁰ Juliana F. Mazzeu,^{81,82,83} Eleuterio Merayo 22 Macías,⁸⁴ Pablo Minguez,^{16,2} Victor Moreno Cuerda,^{85,86} Silviene F. Oliveira,^{87,88,83,89} Eva 23 Ortega-Paino,²³ Mara Parellada,^{18,21,10} Estela Paz-Artal,^{75,76,90} Ney P.C. Santos,⁹¹ Patricia Pérez-24 Matute,92 Patricia Perez,93 M. Elena Pérez-Tomás,27 Teresa Perucho,94 Mel·lina Pinsach-25 Abuin,^{36,35} Guillermo Pita,¹⁷ Ericka N. Pompa-Mera,^{95,96} Gloria L. Porras-Hurtado,⁹⁷ Aurora 26 Pujol,^{98,2,99} Soraya Ramiro León,⁶⁵ Salvador Resino,^{62,11} Marianne R. Fernandes,^{91,100} Emilio 27 Rodríguez-Ruiz,^{101,64} Fernando Rodriguez-Artalejo,^{102,103,41,104} José A. Rodriguez-Garcia,¹⁰⁵ 28 Francisco Ruiz-Cabello,^{67,106,107} Javier Ruiz-Hornillos,^{108,109,110} Pablo Ryan,^{111,112,113,11} José 29 Manuel Soria,⁸⁰ Juan Carlos Souto,¹¹⁴ Eduardo Tamayo,^{115,116,11} Alvaro Tamayo-Velasco,¹¹⁷ 30 Juan Carlos Taracido-Fernandez,⁷⁰ Alejandro Teper,¹¹⁸ Lilian Torres-Tobar,¹¹⁹ Miguel 31 Urioste,¹²⁰ Juan Valencia-Ramos,¹²¹ Zuleima Yáñez,¹²² Ruth Zarate,¹²³ Itziar de Rojas,^{124,125} 32 Agustín Ruiz,^{124,125} Pascual Sánchez,¹²⁶ Luis Miguel Real,¹²⁷ SCOURGE Cohort Group, Encarna 33 Guillen-Navarro,^{27,128,129,130} Carmen Ayuso,^{16,2} Esteban Parra, ¹³¹ José A. Riancho,^{57,58,59,2} 34 Augusto Rojas-Martinez.¹³² Carlos Flores.^{4,133,134,136,*} Pablo Lapunzina.^{2,6,7,136} Ángel 35 Carracedo.^{1,2,5,64,136,**} 36

37 Affiliations

- ¹, Centro Singular de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS),
- 39 Universidade de Santiago de Compostela, Santiago de Compostela, Spain
- 40², CIBERER, ISCIII, Madrid, Spain

- ³, Universidade Federal do Rio Grande do Norte, Departamento de Analises Clinicas e
 Toxicologicas, Natal, Brazil
- ⁴, Genomics Division, Instituto Tecnológico y de Energías Renovables, Santa Cruz de Tenerife,
 Spain
- ⁵, Fundación Pública Galega de Medicina Xenómica, Sistema Galego de Saúde (SERGAS)
 Santiago de Compostela, Spain
- ⁶, Instituto de Genética Médica y Molecular (INGEMM), Hospital Universitario La PazIDIPAZ, Madrid, Spain
- 49⁷, ERN-ITHACA-European Reference Network
- ⁸, Unit of Infectious Diseases, Hospital Universitario 12 de Octubre, Instituto de Investigación
 Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain
- ⁹, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0002), Instituto de
 Salud Carlos III, Madrid, Spain
- ¹⁰, School of Medicine, Universidad Complutense, Madrid, Spain
- 55 ¹¹, CIBERINFEC, ISCIII, Madrid, Spain
- 56 ¹², Hospital General Santa Bárbara de Soria, Soria, Spain
- ¹³, Pediatric Neurology Unit, Department of Pediatrics, Navarra Health Service Hospital,
 Pamplona, Spain
- ¹⁴, Navarra Health Service, NavarraBioMed Research Group, Pamplona, Spain
- 60 ¹⁵, Hospital Universitario Virgen Macarena, Neumología, Seville, Spain
- 61¹⁶, Department of Genetics & Genomics, Instituto de Investigación Sanitaria-Fundación Jiménez
- 62 Díaz University Hospital Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- 63 ¹⁷, Spanish National Cancer Research Centre, Human Genotyping-CEGEN Unit, Madrid, Spain
- ¹⁸, Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health,
- 65 Hospital General Universitario Gregorio Marañón (IiSGM), Madrid, Spain
- 66 ¹⁹, Biocruces Bizkai HRI, Bizkaia, Spain
- 67 ²⁰, Cruces University Hospital, Osakidetza, Bizkaia, Spain
- ²¹, Centre for Biomedical Network Research on Mental Health (CIBERSAM), Instituto de Salud
 Carlos III, Madrid, Spain
- 70 ²², Fundació Docència I Recerca Mutua Terrassa, Barcelona, Spain
- 71 ²³, Spanish National Cancer Research Center, CNIO Biobank, Madrid, Spain
- 72 ²⁴, Hospital General de Occidente, Zapopan Jalisco, Mexico
- 73 ²⁵, Centro Universitario de Tonalá, Universidad de Guadalajara, Tonalá Jalisco, Mexico
- 74 ²⁶, Centro de Investigación Multidisciplinario en Salud, Universidad de Guadalajara, Tonalá
- 75 idisJalisco, Mexico

- 76 ²⁷, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), Murcia, Spain
- ²⁸, Universidad Católica San Antonio de Murcia (UCAM), Murcia, Spain
- ²⁹, Hospital Universitario de Salamanca-IBSAL, Servicio de Medicina Interna-Unidad de
 Enfermedades Infecciosas, Salamanca, Spain
- 80 ³⁰, Universidad de Salamanca, Salamanca, Spain
- 81 ³¹, Escola Tecnica de Saúde, Laboratorio de Vigilancia Molecular Aplicada, Brazil
- ³², Federal University of Pernambuco, Genetics Postgraduate Program, Recife, PE, Brazil
- 83 ³³, Hospital Universitario Mutua Terrassa, Barcelona, Spain
- ³⁴, Instituto de Investigación Sanitaria de Santiago (IDIS), Xenética Cardiovascular, Santiago de
 Compostela, Spain
- 86 ³⁵, CIBERCV, ISCIII, Madrid, Spain
- ³⁶, Cardiovascular Genetics Center, Institut d'Investigació Biomèdica Girona (IDIBGI), Girona,
 Spain
- ³⁷, Medical Science Department, School of Medicine, University of Girona, Girona, Spain
- 90 ³⁸, Hospital Josep Trueta, Cardiology Service, Girona, Spain
- ³⁹, Institute of Biomedicine of Seville (IBiS), Consejo Superior de Investigaciones Científicas
- 92 (CSIC)- University of Seville- Virgen del Rocio University Hospital, Seville, Spain
- ⁴⁰, Departamento de Medicina, Hospital Universitario Virgen del Rocío, Universidad de Sevilla,
 Seville, Spain
- 95⁴¹, CIBERESP, ISCIII, Madrid, Spain
- ⁴², Hospital Universitario de Salamanca-IBSAL, Servicio de Medicina Interna, Salamanca,
 Spain
- 98 ⁴³, Osakidetza, Cruces University Hospital, Bizkaia, Spain
- ⁴⁴, Centre for Biomedical Network Research on Diabetes and Metabolic Associated Diseases
 (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain
- 101 ⁴⁵, University of Pais Vasco, UPV/EHU, Bizkaia, Spain

102 ⁴⁶, Oncology and Genetics Unit, Instituto de Investigacion Sanitaria Galicia Sur, Xerencia de

- 103 Xestion Integrada de Vigo-Servizo Galego de Saúde, Vigo, Spain
- 104 ⁴⁷, Hospital Universitario Río Hortega, Valladolid, Spain
- ⁴⁸, Servicio de Medicina intensiva, Complejo Hospitalario Universitario de A Coruña
 (CHUAC), Sistema Galego de Saúde (SERGAS), A Coruña, Spain
- 107 ⁴⁹, Tecnológico de Monterrey, Monterrey, Mexico

108 ⁵⁰, Otto von Guericke University, Departament of Microgravity and Translational Regenerative

- 109 Medicine, Magdeburg, Germany
- 110 ⁵¹, Hospital Universitario Mostoles, Unidad de Genética, Madrid, Spain

- 111 ⁵², Instituto Aragonés de Ciencias de la Salud (IACS), Zaragoza, Spain
- 112 ⁵³, Instituto Investigación Sanitaria Aragón (IIS-Aragon), Zaragoza, Spain
- ⁵⁴, Preventive Medicine Department, Instituto de Investigacion Sanitaria Galicia Sur, Xerencia
- 114 de Xestion Integrada de Vigo-Servizo Galego de Saúde, Vigo, Spain
- 115 ⁵⁵, Unidad Diagnóstico Molecular. Fundación Rioja Salud, La Rioja, Spain
- 116 ⁵⁶, Hospital Universitario de Salamanca-IBSAL, Servicio de Cardiología, Salamanca, Spain
- 117 ⁵⁷, IDIVAL, Cantabria, Spain
- 118 ⁵⁸, Universidad de Cantabria, Cantabria, Spain
- ⁵⁹, Hospital U M Valdecilla, Cantabria, Spain
- 120⁶⁰, Universidad Nacional de Asunción, Facultad de Politécnica, Paraguay

⁶¹, Urgencias Hospitalarias, Complejo Hospitalario Universitario de A Coruña (CHUAC),
 Sistema Galego de Saúde (SERGAS), A Coruña, Spain

⁶², Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología (CNM), Instituto
 de Salud Carlos III (ISCIII), Madrid, Spain

⁶³, Grupo de Investigación en Interacciones Gen-Ambiente y Salud (GIIGAS) - Instituto de
 Biomedicina (IBIOMED), Universidad de León, León, Spain

- 127 ⁶⁴, IDIS
- 128 ⁶⁵, Hospital Universitario de Getafe, Servicio de Genética, Madrid, Spain
- 129⁶⁶, Ministerio de Salud Ciudad de Buenos Aires, Buenos Aires, Argentina
- ⁶⁷, Hospital Universitario Virgen de las Nieves, Servicio de Análisis Clínicos e Inmunología,
 Granada, Spain
- 132 ⁶⁸, IIS La Fe, Plataforma de Farmacogenética, Valencia, Spain
- 133 ⁶⁹, Universidad de Valencia, Departamento de Farmacología, Valencia, Spain
- 134⁷⁰, Data Analysis Department, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz
- 135 University Hospital Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- 136 ⁷¹, Universidad de los Andes, Facultad de Ciencias, Bogotá, Colombia
- ⁷², SIGEN Alianza Universidad de los Andes Fundación Santa Fe de Bogotá, Bogotá,
 Colombia
- 139⁷³, Hospital General de Segovia, Medicina Intensiva, Segovia, Spain

⁷⁴, Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Urbanización
 Montepríncipe, 28660 Boadilla del Monte, España

142 ⁷⁵, Hospital Universitario 12 de Octubre, Department of Immunology, Madrid, Spain

⁷⁶, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Transplant
 Immunology and Immunodeficiencies Group, Madrid, Spain

- 145 ⁷⁷, Fundación Santa Fe de Bogota, Departamento Patologia y Laboratorios, Bogotá, Colombia
- 146 ⁷⁸, Unidad de Genética y Genómica Islas Baleares, Islas Baleares, Spain
- 147 ⁷⁹, Hospital Universitario Son Espases, Unidad de Diagnóstico Molecular y Genética Clínica,
- 148 Islas Baleares, Spain
- ⁸⁰, Genomics of Complex Diseases Unit, Research Institute of Hospital de la Santa Creu i Sant
 Pau, IIB Sant Pau, Barcelona, Spain
- ⁸¹, Universidade de Brasília, Faculdade de Medicina, Brazil
- 152 ⁸², Programa de Pós-Graduação em Ciências Médicas (UnB), Brazil
- 153 ⁸³, Programa de Pós-Graduação em Ciencias da Saude (UnB), Brazil
- 154 ⁸⁴, Hospital El Bierzo, Unidad Cuidados Intensivos, León, Spain
- 155 ⁸⁵, Hospital Universitario Mostoles, Medicina Interna, Madrid, Spain
- 156⁸⁶, Universidad Francisco de Vitoria, Madrid, Spain
- ⁸⁷, Departamento de Genética e Morfologia, Instituto de Ciências Biológicas, Universidade de
 Brasília, Brazil
- 159 ⁸⁸, Programa de Pós-Graduação em Biologia Animal (UnB), Brazil
- 160 ⁸⁹, Programa de Pós-Graduação Profissional em Ensino de Biologia (UnB), Brazil
- ⁹⁰, Universidad Complutense de Madrid, Department of Immunology, Ophthalmology and ENT,
 Madrid, Spain
- ⁹¹, Universidade Federal do Pará, Núcleo de Pesquisas em Oncologia, Belém, Pará, Brazil
- ⁹², Infectious Diseases, Microbiota and Metabolism Unit, CSIC Associated Unit, Center for
 Biomedical Research of La Rioja (CIBIR), Logroño, Spain
- 166 ⁹³, Inditex, A Coruña, Spain
- 167 ⁹⁴, GENYCA, Madrid, Spain
- 168 ⁹⁵, Instituto Mexicano del Seguro Social (IMSS), Centro Médico Nacional Siglo XXI, Unidad
- de Investigación Médica en Enfermedades Infecciosas y Parasitarias, Mexico City, Mexico

⁹⁶, Instituto Mexicano del Seguro Social (IMSS), Centro Médico Nacional La Raza. Hospital de
 Infectología, Mexico City, Mexico

- ⁹⁷, Clinica Comfamiliar Risaralda, Pereira, Colombia
- ⁹⁸, Bellvitge Biomedical Research Institute (IDIBELL), Neurometabolic Diseases Laboratory,
 L'Hospitalet de Llobregat, Spain
- ⁹⁹, Catalan Institution of Research and Advanced Studies (ICREA), Barcelona, Spain
- 176 ¹⁰⁰, Hospital Ophir Loyola, Departamento de Ensino e Pesquisa, Belém, Pará, Brazil
- 177 ¹⁰¹, Unidad de Cuidados Intensivos, Hospital Clínico Universitario de Santiago (CHUS),
- 178 Sistema Galego de Saúde (SERGAS), Santiago de Compostela, Spain

- 179 ¹⁰², Department of Preventive Medicine and Public Health, School of Medicine, Universidad
- 180 Autónoma de Madrid, Madrid, Spain
- 181 ¹⁰³, IdiPaz (Instituto de Investigación Sanitaria Hospital Universitario La Paz), Madrid, Spain
- 182 ¹⁰⁴, IMDEA-Food Institute, CEI UAM+CSIC, Madrid, Spain
- 183 ¹⁰⁵, Complejo Asistencial Universitario de León, León, Spain
- 184 ¹⁰⁶, Instituto de Investigación Biosanitaria de Granada (ibs GRANADA), Granada, Spain
- ¹⁰⁷, Universidad de Granada, Departamento Bioquímica, Biología Molecular e Inmunología III,
 Granada, Spain
- 187 ¹⁰⁸, Hospital Infanta Elena, Allergy Unit, Valdemoro, Madrid, Spain
- 188 109, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital -
- 189 Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- 190 ¹¹⁰, Faculty of Medicine, Universidad Francisco de Vitoria, Madrid, Spain
- 191 ¹¹¹, Hospital Universitario Infanta Leonor, Madrid, Spain
- ¹¹², Complutense University of Madrid, Madrid, Spain
- 193 ¹¹³, Gregorio Marañón Health Research Institute (IiSGM), Madrid, Spain
- ¹¹⁴, Haemostasis and Thrombosis Unit, Hospital de la Santa Creu i Sant Pau, IIB Sant Pau,
 Barcelona, Spain
- ¹¹⁵, Hospital Clinico Universitario de Valladolid, Servicio de Anestesiologia y Reanimación,
 Valladolid, Spain
- 198 ¹¹⁶, Universidad de Valladolid, Departamento de Cirugía, Valladolid, Spain
- ¹¹⁷, Hospital Clinico Universitario de Valladolid, Servicio de Hematologia y Hemoterapia,
 Valladolid, Spain
- 201 ¹¹⁸, Hospital de Niños Ricardo Gutierrez, Buenos Aires, Argentina
- 202 ¹¹⁹, Fundación Universitaria de Ciencias de la Salud
- 203 ¹²⁰, Spanish National Cancer Research Centre, Familial Cancer Clinical Unit, Madrid, Spain
- 204 ¹²¹, University Hospital of Burgos, Burgos, Spain
- 205 ¹²², Universidad Simón Bolívar, Facultad de Ciencias de la Salud, Barranquilla, Colombia
- 206 ¹²³, Centro para el Desarrollo de la Investigación Científica, Paraguay
- ¹²⁴ ¹⁸³, Research Center and Memory clinic, ACE Alzheimer Center Barcelona, Universitat
 Internacional de Catalunya, Spain
- 209 ^{125 184}, Centre for Biomedical Network Research on Neurodegenerative Diseases (CIBERNED),
- 210 Instituto de Salud Carlos III, Madrid, Spain
- 211 ^{126 185}, CIEN Foundation/Queen Sofia Foundation Alzheimer Center, Madrid, Spain

- ^{127 186}, Hospital Universitario de Valme, Unidad Clínica de Enfermedades Infecciosas y
 Microbiología, Sevilla, Spain
- ^{128 124}, Sección Genética Médica Servicio de Pediatría, Hospital Clínico Universitario Virgen
 de la Arrixaca, Servicio Murciano de Salud, Murcia, Spain
- ¹²⁹ ¹²⁵, Departamento Cirugía, Pediatría, Obstetricia y Ginecología, Facultad de Medicina,
 Universidad de Murcia (UMU), Murcia, Spain
- 218 ¹³⁰¹²⁶, Grupo Clínico Vinculado, Centre for Biomedical Network Research on Rare Diseases
- 219 (CIBERER), Instituto de Salud Carlos III, Madrid, Spain
- ^{131 127} Department of Anthropology, University of Toronto at Mississauga, Mississauga, Ontario,
 Canada.
- ¹³² ¹²⁸, Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey,
 Mexico
- ¹³³ ¹²⁹, Research Unit, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de
 Tenerife, Spain
- ^{134 130}, Centre for Biomedical Network Research on Respiratory Diseases (CIBERES), Instituto
 de Salud Carlos III, Madrid, Spain
- 228 ^{135 131}, These authors contributed equally: Silvia Diz-de Almeida, Raquel Cruz
- 229 ^{136 132}, These authors contributed equally: Carlos Flores, Pablo Lapunzina, Ángel Carracedo
- 230 *Correspondence: cflores@ull.edu.es
- 231 **Correspondence: angel.carracedo@usc.es

233 Abstract

The genetic basis of severe COVID-19 has been thoroughly studied and many genetic 234 235 risk factors shared between populations have been identified. However, reduced sample 236 sizes from non-European groups have limited the discovery of population-specific 237 common risk loci. In this second study nested in the SCOURGE consortium, we have 238 conducted the largest GWAS meta-analysis for COVID-19 hospitalization in admixed 239 Americans, comprising a total of 4,702 hospitalized cases recruited by SCOURGE and 240 other seven participating studies in the COVID-19 Host Genetic Initiative. We 241 identified four genome-wide significant associations, two of which constitute novel loci 242 and first discovered in Latin-American populations (BAZ2B and DDIAS). A trans-ethnic 243 meta-analysis revealed another novel cross-population risk locus in *CREBBP*. Finally, 244 we assessed the performance of a cross-ancestry polygenic risk score in the SCOURGE 245 admixed American cohort.

246 Introduction

To date, more than 50 loci associated to COVID-19 susceptibility, hospitalization, and 247 severity have been identified using genome-wide association studies (GWAS)^{1,2}. The 248 COVID-19 Host Genetics Initiative (HGI) has made significant efforts³ to augment the 249 250 power to identify disease loci by recruiting individuals from diverse populations and conducting a trans-ancestry meta-analysis. Despite this, the lack of genetic diversity and 251 252 a focus on cases of European ancestries still predominate in the studies^{4,5}. Besides, 253 while trans-ancestry meta-analyses are a powerful approach for discovering shared genetic risk variants with similar effects across populations⁶, they may fail to identify 254 255 risk variants that have larger effects on particular underrepresented populations. Genetic 256 disease risk has been shaped by the particular evolutionary history of populations and the environmental exposures⁷. Their action is particularly important for infectious 257

diseases due to the selective constrains that are imposed by the host-pathogen interactions^{8,9}. Literature examples of this in COVID-19 severity includes a *DOCK2* gene variant in East Asians¹⁰, and frequent loss of function variants in *IFNAR1* and *IFNAR2* genes in Polynesian and Inuit populations, respectively^{11,12}.

Including diverse populations in case-control GWAS studies with unrelated participants 262 263 usually require a prior classification of individuals in genetically homogeneous groups, 264 which are typically analysed separately to control the population stratification effects¹³. 265 Populations with recent admixture impose an additional challenge to the GWAS due to 266 their complex genetic diversity and linkage disequilibrium (LD) patterns, requiring the 267 development of alternative approaches and a careful inspection of results to reduce the false positives due to population structure⁷. In fact, there are benefits in study power 268 from modelling the admixed ancestries either locally, at regional scale in the 269 270 chromosomes, or globally, across the genome, depending on factors such as the heterogeneity of the risk variant in frequencies or the effects among the ancestry 271 272 strata¹⁴. Despite the development of novel methods specifically tailored for the analysis of admixed populations¹⁵, the lack of a standardized analysis framework and the 273 274 difficulties to confidently cluster the admixed individuals into particular genetic groups 275 often leads to their exclusion from GWAS.

The Spanish Coalition to Unlock Research on Host Genetics on COVID-19 (SCOURGE) recruited COVID-19 patients between March and December 2020 from hospitals across Spain and from March 2020 to July 2021 in Latin-America (https://www.scourge-covid.org). A first GWAS of COVID-19 severity among Spanish patients of European descent revealed novel disease loci and explored age and sex varying effects of the genetic factors¹⁶. Here we present the findings of a GWAS metaanalysis in admixed American (AMR) populations, comprising individuals from the

283	SCOURGE Latin-American cohort and the HGI studies, which allowed to identify two
284	novel severe COVID-19 loci, BAZ2B and DDIAS. Further analyses modelling the
285	admixture from three genetic ancestral components and performing a trans-ethnic meta-
286	analysis led to the identification of an additional risk locus near CREBBP. We finally
287	assessed a cross-ancestry polygenic risk score model with variants associated with
288	critical COVID-19.

289 Results

290 Meta-analysis of COVID-19 hospitalization in admixed Americans

291 *Study cohorts*

292 Within the SCOURGE consortium, we included 1,608 hospitalized cases and 1,887 293 controls (not hospitalized COVID-19 patients) from Latin-American countries and from recruitments of individuals of Latin-American descend conducted in Spain 294 295 (Supplementary Table 1). Quality control details and estimation of global genetic inferred ancestry (GIA) (supplementary Figure 1) are described in Methods, whereas 296 297 clinical and demographic characteristics of patients included in the analysis are shown in Table 1. Summary statistics from the SCOURGE cohort were obtained under a 298 299 logistic mixed model with the SAIGE model (Methods). Another seven studies 300 participating in the COVID-19 HGI consortium were included in the meta-analysis of 301 COVID-19 hospitalization in admixed Americans (Figure 1).

302 GWAS meta-analysis

We performed a fixed-effects GWAS meta-analysis using the inverse of the variance as weights for the overlapping markers. The combined GWAS sample size consisted of 4,702 admixed AMR hospitalized cases and 68,573 controls.

This GWAS meta-analysis revealed genome-wide significant associations at four risk loci (Table 2, Figure 2), two of which (*BAZ2B* and *DDIAS*) were novel discoveries. Variants of these loci were prioritized by positional and expression quantitative trait loci (eQTL) mapping with FUMA, identifying four lead variants linked to other 310 variants and 31 genes (Supplementary Tables 2-4). A gene-based association test revealed a significant association in *BAZ2B* and in previously known COVID-19 risk loci: *LZTFL1*, *XCR1*, *FYCO1*, *CCR9*, and *IFNAR2* (Supplementary Table 5).

Located within the gene *BAZ2B*, the sentinel variant rs13003835 is an intronic variant associated with an increased risk of COVID-19 hospitalization (Odds Ratio [OR]=1.20, 95% Confidence Interval [CI]=1.12-1.27, p= 3.66×10^{-8}). This association was not previously reported in any GWAS of COVID-19 published to date. Interestingly, rs13003835 did not reach significance (p=0.972) in the COVID-19 HGI trans-ancestry meta-analysis including the five population groups¹. Based on our mapping strategy (see Methods), we also prioritized *PLA2R1*, *LY75*, *WDSUB1*, and *CD302* in this locus.

The other novel risk locus is led by the sentinel variant rs77599934, a rare intronic variant located in chromosome 11 within *DDIAS* and associated with risk of COVID-19 hospitalization (OR=2.27, 95%CI=1.70-3.04, p= 2.26×10^{-8}). The *PRCP* gene was an additional prioritized gene at this locus.

We also observed a suggestive association with rs2601183 in chromosome 15, which is located between *ZNF774* and *IQGAP1* (allele-G OR=1.20, 95%CI=1.12-1.29, p=6.11x10⁻⁸, see Supplementary Table 2), which has not yet been reported in any other GWAS of COVID-19 to date. This sentinel variant is in perfect LD (r^2 =1) with rs601183, an eQTL of *ZNF774* in the lung.

The GWAS meta-analysis also pinpointed two significant variants at known loci, LZTFL1 and FOXP4. The SNP rs35731912 was previously associated with COVID-19 severity in EUR populations¹⁷, and it was mapped to LZTFL1. As for rs2477820, while it is a novel risk variant within gene FOXP4, it has a moderate LD (r^2 =0.295) with rs2496644, which has been linked to COVID-19 hospitalization¹⁸. This is consistent with the effects of LD in tag-SNPs when conducting GWAS in diverse populations.

335 Functional mapping of novel risk variants

336 Bayesian fine mapping

We performed different approaches to narrow down the prioritized loci to a set of most probable genes driving the associations. First, we computed credible sets at the 95% confidence for causal variants and annotated them with VEP and the V2G aggregate scoring (Supplementary Table 6, Supplementary Figure 3). The 95% confidence credible set from the region of chromosome 2 around rs13003835 included 76 variants. However, the approach was unable to converge allocating variants in a 95% confidence credible set for the region in chromosome 11.

344 Colocalization of eQTLs

To determine if the novel genetic risk loci were associated with gene expression in 345 346 relevant tissues (whole blood, lung, lymphocytes, and oesophagus mucosa), we computed the posterior probabilities (PP) of colocalization for overlapping variants 347 348 allocated to the 95% confidence credible set. We used the GTEx v8 tissues as the main 349 expression dataset, although it is important to consider that the eQTL associations were 350 carried out mainly on individuals of EUR ancestries. To confirm the colocalization in other ancestries, we also performed analyses on three expression datasets computed on 351 352 admixed AMR, leveraging data from individuals with high African GIA, high Native-

353 American ancestry, and from a pooled cohort (Methods). Results are shown in the 354 supplementary Table 7.

355 Five genes (LY75, BAZ2B, CD302, WDSUB1, and PLA2R1) were the candidates for eQTL colocalization in the associated region in chromosome 2. However, LY75 356 emerged as the most likely causal gene for this locus since the colocalization in whole 357 358 blood was supported with a PP for H4 (PPH4) of 0.941 and with robust results 359 (supplementary Figure 4). Moreover, this also allowed to prioritize rs12692550 as the 360 most probable causal variant for both traits at this locus with a PP_SNP_H4 of 0.74. 361 Colocalization with gene expression data from admixed AMR validated this finding. 362 LY75 also had evidence of colocalization in lungs (PPH4=0.887) and the esophagus 363 mucosa (PPH4=0.758). However, we could not prioritize a single causal variant in these 364 two other tissues and sensitivity analyses revealed a weak support.

CD302 and BAZ2B were the second and third most likely genes that could drive the association, respectively, according to the colocalization evidence. *CD302* was the most probable according to the high AFR genetic ancestries dataset (supplementary Figure 5).

Despite the chromosome 11 region failing to colocalize with gene expression associations for any of the tissues, the lead variant rs77599934 is in moderate-to-strong LD ($r^2=0.776$) with rs60606421, which is an eQTL associated to a reduced expression of *DDIAS* in the lungs (supplementary Figure 6). The highest PPH4 for *DDIAS* was in the high AFR genetic ancestry expression dataset (0.71).

374 *Transcriptome-wide association study (TWAS)*

Five novel genes, namely *SLC25A37*, *SMARCC1*, *CAMP*, *TYW3*, and *S100A12*(supplementary Table 8) were found significantly associated in the cross-tissue TWAS.

377 To our knowledge, these genes have not been reported previously in any COVID-19 378 TWAS or GWAS analyses published to date. In the single tissue analyses, ATP50 and 379 CXCR6 were significantly associated in lungs, CCR9 was significantly associated in whole blood, and IFNAR2 and SLC25A37 were associated in lymphocytes. 380 381 Likewise, we carried out the TWAS analyses using the models trained in the admixed 382 populations. However, no significant gene-pairs were detected in this case. The 50 383 genes with the lowest p-values are shown in the supplementary Table 9. 384 Genetic architecture of COVID-19 hospitalization in AMR populations 385 Allele frequencies of rs13003835 and rs77599934 across ancestries 386 Neither rs13003835 (BAZ2B) or rs77599934 (DDIAS) were significantly associated in

the COVID-19 HGI B2 cross-population or population-specific meta-analyses. Thus,

we investigated their allele frequencies (AF) across populations and compared theireffect sizes.

390 According to gnomAD v3.1.2, the T allele at rs13003835 (BAZ2B) has an AF of 43% in admixed AMR groups while AF is lower in the EUR populations (16%) and in the 391 global sample (29%). Local ancestry inference (LAI) reported by gnomAD shows that 392 393 within the Native-American component, the risk allele T is the major allele, whereas it 394 is the minor allele within the African and European LAI components. These large 395 differences in AF might be the reason underlying the association found in AMR populations. However, when comparing effect sizes between populations, we found that 396 397 they were in opposite direction between SAS-AMR and EUR-AFR-EAS and that there 398 was a large heterogeneity among them (Figure 3).

rs77599934 (*DDIAS*) had an AF of 1.1% for the G allele in the non-hospitalized
controls (Table 2), in line with the recorded gnomAD AF of 1% in admixed AMR

groups. This variant has potential to be population-specific variant, given the allele 401 402 frequencies in other population groups such as EUR (0% in Finnish, 0.025% in non-403 Finnish), EAS (0%) and SAS (0.042%) and its greater effect size over AFR populations 404 (Figure 3). Examining the LAI, the G allele occurs at 1.1% frequency in the African component while it is almost absent in the Native-American and European. Due to its 405 406 low MAF, rs77599934 was not analyzed in the COVID-19 HGI B2 cross-population 407 meta-analysis and was only present in the HGI B2 AFR population-specific metaanalysis, precluding the comparison (Figure 3). For this reason, we retrieved the variant 408 409 with the lowest p-value within a 50 kb region around rs77599934 in the COVID-19 410 HGI cross-population analysis to investigate if it was in moderate-to-strong LD with our 411 sentinel variant. The variant with the smallest p-value was rs75684040 (OR=1.07, 95%CI=1.03-1.12, p=1.84x10⁻³). Yet, LD calculations using the 1KGP phase 3 dataset 412 indicated that rs77599934 and rs75684040 were poorly correlated ($r^2=0.11$). 413

414 *Cross-population meta-analyses*

We carried out two cross-ancestry inverse variance-weighted fixed-effects metaanalyses with the admixed AMR GWAS meta-analysis results to evaluate whether the discovered risk loci replicated when considering other population groups. In doing so, we also identified novel cross-population COVID-19 hospitalization risk loci.

First, we combined the SCOURGE Latin American GWAS results with the HGI B2 ALL analysis (supplementary Table 10). We refer to this analysis as the SC-HGI_{ALL} meta-analysis. Out of the 40 genome-wide significant loci associated with COVID-19 hospitalization in the last HGI release¹, this study replicated 39 and the association was stronger than in the original study in 29 of those (supplementary Table 11). However, the variant rs13003835 located in *BAZ2B* did not replicate (OR=1.00, 95%CI=0.98-1.03, p=0.644).

426 In this cross-ancestry meta-analysis, we replicated two associations that were not found in HGIv7 albeit they were sentinel variants in the latest GenOMICC meta-analysis². We 427 428 found an association at the CASC20 locus led by the variant rs2876034 (OR=0.95, 95%CI=0.93-0.97, p= 2.83×10^{-8}). This variant is in strong LD with the sentinel variant 429 of that study (rs2326788, $r^2=0.92$), which was associated with critical COVID-19². 430 Besides, this meta-analysis identified the variant rs66833742 near ZBTB7A associated 431 with COVID-19 hospitalization (OR=0.94, 95%CI=0.92-0.96, p=2.50x10⁻⁸). Notably, 432 rs66833742 or its perfect proxy rs67602344 ($r^2=1$) are also associated with upregulation 433 434 of ZBTB7A in whole blood and in esophagus mucosa. This variant was previously associated with COVID-19 hospitalization². 435

436 In a second analysis, we also explored the associations across the defined admixed 437 AMR, EUR, and AFR ancestral sources by combining through meta-analysis the 438 SCOURGE Latin American GWAS results with the HGI studies in EUR, AFR, and admixed AMR, and excluding those from EAS and SAS (Supplementary Table 12). We 439 440 refer to this as the SC-HGI_{3POP} meta-analysis. The association at rs13003835 (BAZ2B, 441 OR=1.01, 95%CI=0.98-1.03, p=0.605) was not replicated and rs77599934 near DDIAS could not be assessed, although the association at the ZBTB7A locus was confirmed 442 (rs66833742, OR=0.94, 95%CI=0.92-0.96, p=1.89x10⁻⁸). The variant rs76564172 443 located near CREBBP also reached statistical significance (OR=1.31, 95% CI=1.25-444 1.38, $p=9.64 \times 10^{-9}$). The sentinel variant of the region linked to *CREBBP* (in the trans-445 446 ancestry meta-analysis) was also subjected a Bayesian fine mapping (supplementary 447 Table 6) and colocalization with eQTLs under the GTEx v8 MASHR models in lungs, 448 esophagus mucosa, whole blood, and transformed lymphocytes. Eight variants were included in the credible set for the region in chromosome 16 (meta-analysis SC-449 HGI_{3POP}), although *CREBBP* did not colocalize in any of the tissues. 450

451 Polygenic risk score models

Using the 49 variants associated with disease severity that are shared across populations 452 according to the HGIv7, we constructed a polygenic risk score (PGS) model to assess its 453 generalizability in the admixed AMR (Supplementary Table 13). First, we calculated 454 455 the PGS for the SCOURGE Latin Americans and explored the association with COVID-19 hospitalization under a logistic regression model. The PGS model was 456 associated with a 1.48-fold increase in COVID-19 hospitalization risk per every PGS 457 458 standard deviation. It also contributed to explain a slightly larger variance (R2=1.07%) 459 than the baseline model.

Subsequently, we divided the individuals into PGS deciles and percentiles to assess their risk stratification. The median percentile among controls was 40, while in cases it was 63. Those in the top PGS decile exhibited a 5.90-fold (95% CI=3.29-10.60, $p=2.79x10^{-9}$) greater risk compared to individuals in the lowest decile, whereas the effects for the rest of the comparisons were much milder.

We also examined the distribution of PGS scores across a 5-level severity scale to 465 further determine if there was any correspondence between clinical severity and genetic 466 risk. Median PGS scores were lower in the asymptomatic and mild groups, whereas 467 higher median scores were observed in the moderate, severe, and critical patients 468 469 (Figure 4). We fitted a multinomial model using the asymptomatic class as reference 470 and calculated the OR for each category (Supplementary Table 13), observing that the 471 disease genetic risk was similar among asymptomatic, mild, and moderate patients. 472 Given that the PGS was built with variants associated with critical disease and/or 473 hospitalization and that the categories severe and critical correspond to hospitalized patients, these results underscore the ability of cross-ancestry PGS for risk stratification 474 even in an admixed population. 475

Finally, we incorporated the novel lead SNPs from our AMR meta-analysis (rs13003835, rs2477820, and rs77599934) into the PGS model. Their inclusion in the model contributed to explain a larger variance (R2=1.74%) than the model without them. This result, however, should be taken with caution given the risk of overfitting due to the use of the same subjects both for the derivation and testing of the variants.

481

482 **DISCUSSION**

483 We have conducted the largest GWAS meta-analysis of COVID-19 hospitalization in 484 admixed AMR to date. While the genetic risk basis discovered for COVID-19 is largely 485 shared among populations, trans-ancestry meta-analyses on this disease have primarily 486 included EUR samples. This dominance of GWAS in Europeans, and the subsequent bias in sample sizes, can mask population-specific genetic risks (i.e., variants that are 487 488 monomorphic in some populations) or be less powered to detect risk variants having 489 higher allele frequencies in population groups other than Europeans. In this sense, after 490 combining data from admixed AMR patients, we found two risk loci which are first discovered in a GWAS of Latin-American populations. Interestingly, the sentinel 491 492 variant rs77599934 in the DDIAS gene is a rare coding variant (~1% for allele G) with a 493 large effect on COVID-19 hospitalization that is nearly monomorphic in most of the 494 other populations. This has likely led to its exclusion from the cross-populations metaanalyses conducted to date, remaining undetectable. 495

Fine mapping of the region harbouring *DDIAS* did not reveal further information about which gene could be the more prone to be causal, or about the functional consequences of the risk variant. However, *DDIAS*, known as damage-induced apoptosis suppressor gene, is itself a plausible candidate gene. It has been linked to DNA damage repair

500 mechanisms: research showed that depletion of DDIAS led to an increase of ATM phosphorylation and the formation of p53-binding protein (53BP1) foci, a known 501 502 biomarker of DNA double-strand breaks, suggesting a potential role in double-strand break repair¹⁹. Similarly, elevated levels of phosphorylated nuclear histone $2AX\gamma$ were 503 detected after knocking down DDIAS, further emphasizing its role in DNA damage 20 . 504 505 Interestingly, a study found that the infection by SARS-CoV-2 also triggered the 506 phosphorylation of the ATM kinase and inhibited repair mechanisms, causing the accumulation of DNA damage²¹. This same study reported the activation of the pro-507 508 inflammatory pathway p38/MAPK by the virus, which was as well prompted after knocking-down DDIAS²⁰. 509

510 Regarding lung function, the role of DDIAS in lung cancer has been widely studied. It 511 has been proposed as a potential biomarker for lung cancer after finding that it interacts with STAT3 in lung cancer cells, regulating $IL-6^{22,23}$ and thus mediating inflammatory 512 processes. Furthermore, another study determined that its blockade inhibited lung 513 cancer cell growth²⁰. The sentinel variant was in strong LD with an eQTL that reduced 514 515 gene expression of DDIAS in lung, and our findings suggest that DDIAS gene may be indeed involved in viral response. Hence, one reasonable hypothesis is that reduced 516 expression of DDIAS could potentially facilitate SARS-CoV-2 infection through the 517 downregulation of pathways involved in DNA repairment and inflammation. Another 518 519 prioritized gene from this region was *PRCP*, an angiotensinase that has been linked to 520 hypertension and for which a hypothesis on its role on COVID-19 progression has been raised^{24,25}. 521

The risk region found in chromosome 2 prioritized more than one gene. The lead variant rs13003835 is located within *BAZ2B*. *BAZ2B* encodes one of the regulatory subunits of the Imitation switch (ISWI) chromatin remodelers²⁶ constituting the BRF-1/BRF-5

525 complexes with SMARCA1 and SMARCA5, respectively, and the association signal colocalized with eQTLs in whole blood. The gene LY75 (encoding the lymphocyte 526 527 antigen 75) also colocalized with eQTLs in whole blood, esophagus mucosa, and lung tissues. Lymphocyte antigen 75 is involved in immune processes through antigen 528 presentation in dendritic cells and endocytosis²⁷, and has been associated with 529 inflammatory diseases, representing also a compelling candidate for the region. 530 531 Increased expression of LY75 has been detected within hours after the infection by SARS-CoV- $2^{28,29}$. Lastly, the signal of *CD302* colocalized in individuals with high 532 533 AFR ancestral admixture in whole blood. This gene is located in the vicinity of LY75 534 and both conform the readthrough LY75-CD302. It is worth noting that differences in 535 AF for this variant suggest that analyses in AMR populations might be more powered to detect the association, supporting the necessity of population-specific studies. 536

A third novel risk region was observed in chromosome 15, between the genes *IQGAP1*and *ZNF774*, although not reaching genome-wide significance.

539 Secondary analyses revealed five TWAS-associated genes, some of which have been already linked to severe COVID-19. In a comprehensive multi-tissue gene expression 540 profiling study³⁰, decreased expression of CAMP and S100A8/S100A9 genes in COVID-541 19 severe patients was observed, while another study detected the upregulation of 542 543 SCL25A37 among severe COVID-19 patients³¹. SMARCC1 is a subunit of the SWI/SNF chromatin remodelling complex that has been identified as pro-viral for SARS-CoV-2 544 and other coronavirus strains through a genome-wide screen³². This complex is crucial 545 for ACE2 expression and the viral entry in the $cell^{33}$. 546

To explore the genetic architecture of the trait among admixed AMR populations, we performed two cross-ancestry meta-analyses including the SCOURGE Latin-American cohort GWAS findings. We found that the two novel risk variants did not associate with

550 COVID-19 hospitalization outside the population-specific meta-analysis, highlighting 551 the importance of complementing trans-ancestry meta-analyses with group-specific 552 analyses. Notably, this analysis did not replicate the association at the DSTYK locus, which was associated with severe COVID-19 in Brazilian individuals with higher 553 European admixture³⁴. This lack of replication supports the initial hypothesis of that 554 555 study suggesting that the risk haplotype derived from European populations, as we have 556 reduced the weight of this ancestral contribution in our study by excluding those individuals. 557

558 Moreover, these cross-ancestry meta-analyses pointed to three loci that were not 559 genome-wide significant in the HGIv7 ALL meta-analysis: a novel locus at CREBBP, 560 and two loci at ZBTB7A and CASC20 that were reported in another meta-analysis. 561 CREBBP and ZBTB7A achieved a stronger significance when considering only EUR, AFR, and admixed AMR GIA groups. According to a recent study, elevated levels of 562 the ZBTB7A gene promote a quasi-homeostatic state between coronaviruses and host 563 cells, preventing cell death by regulating oxidative stress pathways³⁵. This gene is 564 involved in several signalling pathways, such as B and T cell differentiation³⁶. On a 565 566 separate note, *CREBBP* encodes the CREB binding protein (CBP), involved in transcription activation, that is known to positively regulate the type I interferon 567 response through virus-induced phosphorylation of IRF-3³⁷. Besides, the CREBP/CBP 568 interaction has been implicated in SARS-CoV-2 infection³⁸ via the cAMP/PKA 569 570 pathway. In fact, cells with suppressed CREBBP gene expression exhibit reduced replication of the so called Delta and Omicron SARS-CoV-2 variants³⁸. 571

The cross-population PGS model effectively stratified individuals based on their genetic risk and demonstrated consistency with the clinical severity classification of the patients. The inclusion of the new variants in the PGS model slightly improved the

575 predictive value of the PGS. However, it is important to confirm this last finding in an 576 external admixed AMR cohort to address potential overfitting arising from using the 577 same individuals both for the discovery of the associations and for testing the model.

This study is subject to limitations, mostly concerning the sample recruitment and 578 579 composition. The SCOURGE Latino-American sample size is small and the GWAS is underpowered. Another limitation is the difference in case-control recruitment across 580 sampling regions that, yet controlled for, may reduce the ability to observe significant 581 582 associations driven by different compositions of the populations. In this sense, the 583 identified risk loci might not replicate in a cohort lacking any of the parental population 584 sources from the three-way admixture. Likewise, we could not explicitly control for 585 socio-environmental factors that could have affected COVID-19 spread and 586 hospitalization rates, although genetic principal components are known to capture nongenetic factors. Finally, we must acknowledge the lack of a replication cohort. We have 587 used all the available GWAS data for COVID-19 hospitalization in admixed AMR in 588 589 this meta-analysis due to the low number of studies conducted. Therefore, we had no 590 studies to replicate or validate the results. These concerns may be addressed in the 591 future by including more AMR GWAS studies in the meta-analysis, both by involving diverse populations in study designs and by supporting research from countries in Latin-592 593 America.

This study provides novel insights into the genetic basis of COVID-19 severity, emphasizing the importance of considering host genetic factors through using non-European populations, especially of admixed sources. Such complementary efforts can pin down new variants and increase our knowledge on the host genetic factors of severe COVID-19.

599 Materials and methods

600 GWAS in Latin Americans from SCOURGE

601 The SCOURGE Latin American cohort

602 A total of 3,729 of COVID-19 positive cases were recruited across five countries from 603 Latin America (Mexico, Brazil, Colombia, Paraguay, and Ecuador) by 13 participating centres (supplementary Table 1) from March 2020 to July 2021. In addition, we 604 included 1,082 COVID-19 positive individuals recruited between March and December 605 606 2020 in Spain who either had evidence of origin from a Latin American country or 607 showed inferred genetic admixture between AMR, EUR, and AFR (with < 0.05%608 SAS/EAS). These individuals were excluded from a previous SCOURGE study that focused on participants with European genetic ancestries¹⁶. We used hospitalization as a 609 610 proxy for disease severity and defined as cases those COVID-19 positive patients that underwent hospitalization as a consequence of the infection and used as controls those 611 that did not need hospitalization due to COVID-19. 612

Samples and data were collected with informed consent after the approval of the Ethics
and Scientific Committees from the participating centres and by the Galician Ethics
Committee Ref 2020/197. Recruitment of patients from IMSS (in Mexico, City), was
approved by of the National Comitte of Clinical Research, from Instituto Mexicano del
Seguro Social, Mexico (protocol R-2020-785-082).

Samples and data were processed following normalized procedures. The REDCap electronic data capture tool^{39,40}, hosted at Centro de Investigación Biomédica en Red (CIBER) from the Instituto de Salud Carlos III (ISCIII), was used to collect and manage demographic, epidemiological, and clinical variables. Subjects were diagnosed for COVID-19 based on quantitative PCR tests (79.3%), or according to clinical (2.2%) or laboratory procedures (antibody tests: 16.3%; other microbiological tests: 2.2%).

624 SNP array genotyping

Genomic DNA was obtained from peripheral blood and isolated using the Chemagic
DNA Blood 100 kit (PerkinElmer Chemagen Technologies GmbH), following the
manufacturer's recommendations.

Samples were genotyped with the Axiom Spain Biobank Array (Thermo Fisher Scientific) following the manufacturer's instructions in the Santiago de Compostela Node of the National Genotyping Center (CeGen-ISCIII; http://www.usc.es/cegen). This array contains probes for genotyping a total of 757,836 SNPs. Clustering and genotype calling were performed using the Axiom Analysis Suite v4.0.3.3 software.

633 *Quality control steps and variant imputation*

A quality control (QC) procedure using PLINK 1.9⁴¹ was applied to both samples and 634 the genotyped SNPs. We excluded variants with a minor allele frequency (MAF) < 1%, 635 a call rate <98%, and markers strongly deviating from Hardy-Weinberg equilibrium 636 expectations ($p < 1 \times 10^{-6}$) with mid-p adjustment. We also explored the excess of 637 638 heterozygosity to discard potential cross-sample contaminations. Samples missing >2% of the variants were filtered out. Subsequently, we kept the autosomal SNPs and 639 640 removed high LD regions and conducted LD-pruning (windows of 1,000 SNPs, with step size of 80 and r^2 threshold of 0.1) to assess kinship and estimate the global 641 642 ancestral proportions. Kinship was evaluated based on IBD values, removing one 643 individual from each pair with PI HAT>0.25 that showed a Z0, Z1, and Z2 coherent 644 pattern (according to the theoretical expected values for each relatedness level). Genetic 645 principal components (PCs) were calculated with PLINK with the subset of LD pruned 646 variants.

Genotypes were imputed with the TOPMed version r2 reference panel (GRCh38) using the TOPMed Imputation Server and variants with Rsq<0.3 or with MAF<1% were filtered out. A total of 4,348 individuals and 10,671,028 genetic variants were included in the analyses.

651 *Genetic admixture estimation*

Global genetic inferred ancestry (GIA), referred to the genetic similarity to the used 652 reference individuals, was estimated with the ADMIXTURE⁴² v1.3 software following 653 a two-step procedure. First, we randomly sampled 79 European (EUR) and 79 African 654 (AFR) samples from The 1000 Genomes Project (1KGP)⁴³ and merged them with the 655 79 Native American (AMR) samples from Mao et al.⁴⁴ keeping the biallelic SNPs. LD-656 657 pruned variants were selected from this merge using the same parameters as in the QC. 658 We then run an unsupervised analysis with K=3 to redefine and homogenize the clusters 659 and to compose a refined reference for the analyses, by applying a threshold of $\geq 95\%$ 660 of belonging to a particular cluster. As a result of this, 20 AFR, 18 EUR, and 38 AMR 661 individuals were removed. The same LD-pruned variants data from the remaining 662 individuals were merged with the SCOURGE Latin American cohort to perform a supervised clustering and estimated admixture proportions. A total of 471 samples from 663 664 the SCOURGE cohort with >80% estimated European GIA were removed to reduce the 665 weight of the European ancestral component, leaving a total of 3,512 admixed American (AMR) subjects for downstream analyses. 666

667 Association analysis

Results for the SCOURGE Latin Americans GWAS were obtained testing for COVID-19 hospitalization as a surrogate of severity. To accommodate the continuum of GIA in the cohort, we opted for a joint testing of all the individuals as a single study using a

671	mixed regression model, as this approach has demonstrated a greater power and to
672	sufficiently control population structure ⁴⁵ . The SCOURGE cohort consisted of 3,512
673	COVID-19 positive patients: cases (n=1,625) were defined as hospitalized COVID-19
674	patients and controls (n=1,887) as non-hospitalized COVID-19 positive patients.
675	Logistic mixed regression models were fitted using the SAIGEgds ⁴⁶ package in R,
676	which implements the two-step mixed SAIGE ⁴⁷ model methodology and the SPA test.
677	Baseline covariables included sex, age, and the first 10 PCs. To account for a potential
678	heterogeneity in the recruitment and hospitalization criteria across the participating
679	countries, we adjusted the models by groups of the recruitment areas classified in six
680	categories: Brazil, Colombia, Ecuador, Mexico, Paraguay, and Spain. This dataset has

not been used in any previously GWAS of COVID-19 published to date.

682 Meta-analysis of Latin-American populations

683 The results of the SCOURGE Latin American cohort were meta-analyzed with the 684 AMR HGI-B2 data, conforming our primary analysis. Summary results from the HGI freeze 7 B2 analysis corresponding to the admixed AMR population were obtained from 685 the public repository (April 8, 2022: https://www.covid19hg.org/results/r7/), summing 686 687 up 3,077 cases and 66,686 controls from seven contributing studies. We selected the B2 phenotype definition because it offered more power and the presence of population 688 controls not ascertained for COVID-19 does not have a drastic impact in the association 689 690 results.

The meta-analysis was performed using an inverse-variance weighting method in METAL⁴⁸. Average allele frequency was calculated and variants with low imputation quality (Rsq<0.3) were filtered out, leaving 10,121,172 variants for meta-analysis.

- 694 Heterogeneity between studies was evaluated with the Cochran's-Q test. The inflation
- 695 of results was assessed based on a genomic control (lambda).

696 Definition of the genetic risk loci and putative functional impact

697 Definition of lead variant and novel loci

To define the lead variants in the loci that were genome-wide significant, an LD-698 clumping was performed on the meta-analysis data using a threshold p-value $< 5 \times 10^{-8}$, 699 clump distance=1500 kb, independence set at a threshold $r^2=0.1$ and used the 700 701 SCOURGE cohort genotype data as LD reference panel. Independent loci were deemed as a novel finding if they met the following criteria: 1) p-value $<5x10^{-8}$ in the meta-702 analysis and p-value> 5×10^{-8} in the HGI B2 ALL meta-analysis or in the HGI B2 AMR 703 and AFR and EUR analyses when considered by separate; 2) Cochran's Q-test for 704 heterogeneity of effects is $<0.05/N_{loci}$, where N_{loci} is the number of independent variants 705 with $p < 5x10^{-8}$; and 3) the nearest gene has not been previously described in the latest 706 HGIv7 update. 707

708 Annotation and initial mapping

Functional annotation was done with FUMA⁴⁹ for those variants with a p-value $<5x10^{-8}$ 709 or in moderate-to-strong LD $(r^2>0.6)$ with the lead variants, where the LD was 710 calculated from the 1KGP AMR panel. Genetic risk loci were defined by collapsing 711 LD-blocks within 250 kb. Then, genes, scaled CADD v1.4 scores, and RegulomeDB 712 713 v1.1 scores were annotated for the resulting variants with ANNOVAR in FUMA⁴⁹. Gene-based analysis was also performed using MAGMA⁵⁰ as implemented in FUMA, 714 715 under the SNP-wide mean model using the 1KGP AMR reference panel. Significance was set at a threshold $p<2.66 \times 10^{-6}$ (which assumes that variants can be mapped to a total 716 717 of 18,817 genes).

FUMA allowed us to perform an initial gene mapping by two approaches: (1) positional
mapping, which assigns variants to genes by physical distance using 10-kb windows;
and (2) eQTL mapping based on GTEx v.8 data from whole blood, lungs, lymphocytes,
and oesophagus mucosa tissues, establishing a False Discovery Rate (FDR) of 0.05 to
declare significance for variant-gene pairs.

Subsequently, to assign the variants to the most likely gene driving the association, we
refined the candidate genes by fine mapping the discovered regions and implementing
functional mapping.

726 To conduct a Bayesian fine mapping, credible sets for the genetic loci considered novel 727 findings were calculated on the results from each of the three meta-analyses to identify a 728 subset of variants most likely containing the causal variant at 95% confidence level, 729 assuming that there is a single causal variant and that it has been tested. We used corrcoverage (https://cran.rstudio.com/web/packages/corrcoverage/index.html) for R to 730 731 calculate the posterior probabilities of the variant being causal for all variants with an 732 r^{2} >0.1 with the leading SNP and within 1 Mb except for the novel variant in chromosome 19, for which we used a window of 0.5 Mb. Variants were added to the 733 734 credible set until the sum of the posterior probabilities was ≥ 0.95 . VEP 735 (https://www.ensembl.org/info/docs/tools/vep/index.html) and the V2G aggregate 736 scoring from Open Targets Genetics (https://genetics.opentargets.org) were used to 737 annotate the biological function of the variants contained in the fine-mapped credible 738 sets

739 *Colocalization analysis*

We also conducted colocalization analyses to identify the putative causal genes that could act through the regulation of gene expression. FUMA's eQTL mapping enabled

the identification of genes whose expression was associated with the variants in whole blood, lungs, lymphocytes, and oesophagus mucosa tissues. We combined this information with the VEP and V2G aggregate scoring to prioritize genes. For the finemapping regions, we included the variants within the calculated credible sets. In the cases where the fine mapping was unsuccessful, we considered variants within a 0.2 Mb window of the lead variant.

For each prioritized gene, we then run COLOC⁵¹ to assess the evidence of 748 749 colocalization between association signals and the eQTLs in each tissue, when at least 750 one variant overlapped between them. COLOC estimates the posterior probability of 751 two traits sharing the same causal variant in a locus. Prior probabilities of a variant being associated to COVID-19 phenotype (p1) and gene expression (p2) were set at 752 1×10^{-4} , while pp2 was set at 1×10^{-6} as they are robust thresholds⁵². The posterior 753 probability of colocalization (PP4) > 0.75 and a ratio PP4/PP3>3 were used as the 754 criteria to support evidence of colocalization. Additionally, a threshold of PP4.SNP >0.5 755 756 was chosen for causal variant prioritization. In cases were colocalization of a single variant failed, we computed the 95% credible sets. The eQTL data was retrieved from 757 GTEx v8 and only significant variant-gene pairs were considered in the analyses. 758

Colocalization in whole-blood was also performed using the recent published gene expression datasets derived from a cohort of African Americans, Puerto Ricans, and Mexican Americans (GALA II-SAGE)⁵³. We used the results from the pooled cohort for the three discovered loci, and from the AFRHp5 (African genetic ancestry>50%) and IAMHp5 (Native American genetic ancestry>50%) cohorts for the risk loci in chromosomes 2 and 11. Results are shown in the Supplementary Table 10.

765 Sensitivity plots are shown in supplementary Figures 4 and 5.

766 Transcription-wide association studies

Transcriptome-wide association studies (TWAS) were conducted using the pretrained 767 prediction models with MASHR-computed effect sizes on GTEx v8 datasets^{54,55}. 768 Results from the Latin-American meta-analysis were harmonized and integrated with 769 the prediction models through S-PrediXcan⁵⁶ for lungs, whole blood, lymphocytes and 770 oesophagus mucosa tissues. Statistical significance was set at p-value<0.05 divided by 771 772 the number of genes that were tested for each tissue. Subsequently, we leveraged results 773 for all 49 tissues and run a multi-tissue TWAS to improve power for association, as demonstrated recently⁵⁷. TWAS was also conducted with the MASHR models for 774 whole-blood in the pooled admixed AMR from the GALA and SAGE studies⁵³. 775

776 Cross-population meta-analyses

We conducted two additional meta-analyses to investigate the ability of combining populations to replicate our discovered risk loci. This methodology enabled the comparison of effects and the significance of associations in the novel risk loci between the results from analyses that included or excluded other population groups.

The first meta-analysis comprised the five populations analysed within HGI (B2-ALL). Additionally, to evaluate the three GIA components within the SCOURGE Latin-American cohort⁵⁸, we conducted a meta-analysis of the admixed AMR, EUR, and AFR cohorts (B2). All summary statistics were retrieved from the HGI repository. We applied the same meta-analysis methodology and filters as in the admixed AMR metaanalysis. Novel variants from these meta-analyses were fine-mapped and colocalized with gene expression.

788 Cross-population Polygenic Risk Score

A polygenic risk score (PGS) for critical COVID-19 was derived combining the variants associated with hospitalization or disease severity that have been discovered to date. We curated a list of lead variants that were: 1) associated to either severe disease or hospitalization in the latest HGIv7 release¹ (using the hospitalization weights); or 2) associated to severe disease in the latest GenOMICC meta-analysis² that were not reported in the latest HGI release. A total of 49 markers were used in the PGS model (see supplementary Table 13) since two variants were absent from our study.

796 Scores were calculated and normalized for the SCOURGE Latin-American cohort with 797 PLINK 1.9. This cross-ancestry PGS was used as a predictor for hospitalization 798 (COVID-19 positive that were hospitalized vs. COVID-19 positive that did not necessitate hospital admission) by fitting a logistic regression model. Prediction 799 accuracy for the PGS was assessed by performing 500 bootstrap resamples of the 800 801 increase in the pseudo-R-squared. We also divided the sample in deciles and percentiles to assess risk stratification. The models were fit for the dependent variable adjusting for 802 803 sex, age, the first 10 PCs, and the sampling region (in the Admixed AMR cohort) with 804 and without the PGS, and the partial pseudo-R2 was computed and averaged among the resamples. 805

806 A clinical severity scale was used in a multinomial regression model to further evaluate 807 the power of this cross-ancestry PGS for risk stratification. This severity strata were defined as follows: 0) asymptomatic; 1) mild, that is, with symptoms, but without 808 809 pulmonary infiltrates or need of oxygen therapy; 2) moderate, that is, with pulmonary 810 infiltrates affecting <50% of the lungs or need of supplemental oxygen therapy; 3) 811 severe disease, that is with hospital admission and PaO₂<65 mmHg or SaO₂<90%, PaO₂/FiO₂<300, SaO₂/FiO₂<440, dyspnea, respiratory frequency≥22 bpm, and 812 infiltrates affecting >50% of the lungs; and 4) critical disease, that is with an admission 813

to the ICU or need of mechanical ventilation (invasive or non-invasive). We also
included the novel risk variants as predictors alongside the PRS to determine if they
provided increased prediction ability.

817 Data availability

- 818 Summary statistics from the SCOURGE Latin-American GWAS will be available at
- 819 https://github.com/CIBERER/Scourge-COVID19.
- 820

821 Funding

- 822 Instituto de Salud Carlos III (COV20_00622 to A.C., COV20/00792 to M.B.,
- 823 COV20_00181 to C.A., COV20_1144 to M.A.J.S. and A.F.R., PI20/00876 to C.F.);
- 824 European Union (ERDF) 'A way of making Europe'. Fundación Amancio Ortega,
- Banco de Santander (to A.C.), Estrella de Levante S.A. and Colabora Mujer Association
- 826 (to E.G.-N.) and Obra Social La Caixa (to R.B.); Agencia Estatal de Investigación
- 827 (RTC-2017-6471-1 to C.F.), Cabildo Insular de Tenerife (CGIEU0000219140
- ⁸²⁸ 'Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19' to C.F.)
- and Fundación Canaria Instituto de Investigación Sanitaria de Canarias (PIFIISC20/57
- 830 to C.F.).
- 831 SD-DA was supported by a Xunta de Galicia predoctoral fellowship.

832 Author contributions

- 833 Study design: RC, AC, CF. Data collection: SCOURGE cohort group. Data analysis:
- 834 SD-DA, RC, ADL, CF, JML-S. Interpretation: SD-DA, RC, ADL. Drafting of the
- 835 manuscript: SD-DA, RC, ADL, CF, AR-M, AC. Critical revision of the manuscript:

836 SD-DA, RC, ADL, AC, CF, JAR, AR-M, PL. Approval of the final version of the

837 publication: all co-authors.

838 Acknowledgements

- 839 The contribution of the Centro National de Genotipado (CEGEN), and Centro de
- 840 Supercomputación de Galicia (CESGA) for funding this project by providing
- supercomputing infrastructures, is also acknowledged. Authors are also particularly
- grateful for the supply of material and the collaboration of patients, health professionals
- from participating centers and biobanks. Namely Biobanc-Mur, and biobancs of the
- 844 Complexo Hospitalario Universitario de A Coruña, Complexo Hospitalario
- 845 Universitario de Santiago, Hospital Clínico San Carlos, Hospital La Fe, Hospital
- 846 Universitario Puerta de Hierro Majadahonda—Instituto de Investigación Sanitaria
- 847 Puerta de Hierro—Segovia de Arana, Hospital Ramón y Cajal, IDIBGI, IdISBa, IIS
- 848 Biocruces Bizkaia, IIS Galicia Sur. Also biobanks of the Sistema de Salud de Aragón,
- 849 Sistema Sanitario Público de Andalucía, and Banco Nacional de ADN.

850

851 **References**

Initiative, T. C.-19 H. G. & Ganna, A. A second update on mapping the human genetic
 architecture of COVID-19. 2022.12.24.22283874 Preprint at

- 854 https://doi.org/10.1101/2022.12.24.22283874 (2023).
- 855 2. GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19 |
 856 Nature. https://www.nature.com/articles/s41586-023-06034-3.
- 857 3. Niemi, M. E. K. *et al.* Mapping the human genetic architecture of COVID-19. *Nature*858 600, 472–477 (2021).
- 859 4. Popejoy, A. B. & Fullerton, S. M. Genomics is failing on diversity. *Nature* 538, 161–164
 860 (2016).
- Sirugo, G., Williams, S. M. & Tishkoff, S. A. The Missing Diversity in Human Genetic
 Studies. *Cell* 177, 26–31 (2019).

863 6. Li, Y. R. & Keating, B. J. Trans-ethnic genome-wide association studies: advantages and 864 challenges of mapping in diverse populations. Genome Med. 6, 91 (2014). 865 7. Rosenberg, N. A. et al. Genome-wide association studies in diverse populations. Nat. 866 Rev. Genet. 11, 356-366 (2010). 867 Kwok, A. J., Mentzer, A. & Knight, J. C. Host genetics and infectious disease: new tools, 8. 868 insights and translational opportunities. Nat. Rev. Genet. 22, 137-153 (2021). 869 9. Karlsson, E. K., Kwiatkowski, D. P. & Sabeti, P. C. Natural selection and infectious 870 disease in human populations. Nat. Rev. Genet. 15, 379-393 (2014). 871 10. Namkoong, H. et al. DOCK2 is involved in the host genetics and biology of severe 872 COVID-19. Nature 609, 754-760 (2022). 873 Bastard, P. et al. A loss-of-function IFNAR1 allele in Polynesia underlies severe viral 11. 874 diseases in homozygotes. J. Exp. Med. 219, e20220028 (2022). 875 12. Duncan, C. J. A. et al. Life-threatening viral disease in a novel form of autosomal 876 recessive IFNAR2 deficiency in the Arctic. J. Exp. Med. 219, e20212427 (2022). 877 Peterson, R. E. et al. Genome-wide Association Studies in Ancestrally Diverse 13. 878 Populations: Opportunities, Methods, Pitfalls, and Recommendations. Cell 179, 589–603 879 (2019). 880 14. Mester, R. et al. Impact of cross-ancestry genetic architecture on GWAS in admixed 881 populations. 2023.01.20.524946 Preprint at https://doi.org/10.1101/2023.01.20.524946 882 (2023). 883 15. Tractor uses local ancestry to enable the inclusion of admixed individuals in GWAS and 884 to boost power | Nature Genetics. https://www.nature.com/articles/s41588-020-00766-y. 885 16. Cruz, R. et al. Novel genes and sex differences in COVID-19 severity. Hum. Mol. Genet. 886 **31**, 3789–3806 (2022). 887 17. Degenhardt, F. et al. Detailed stratified GWAS analysis for severe COVID-19 in four 888 European populations. Hum. Mol. Genet. 31, 3945-3966 (2022). 889 18. Whole-genome sequencing reveals host factors underlying critical COVID-19 | Nature. 890 https://www.nature.com/articles/s41586-022-04576-6. 891 19. Evolution-based screening enables genome-wide prioritization and discovery of DNA 892 repair genes | PNAS. https://www.pnas.org/doi/full/10.1073/pnas.1906559116. 893 20. Human Noxin is an anti-apoptotic protein in response to DNA damage of A549 894 non-small cell lung carcinoma - Won - 2014 - International Journal of Cancer - Wiley Online 895 Library. https://onlinelibrary.wiley.com/doi/10.1002/ijc.28600. 896 21. Gioia, U. et al. SARS-CoV-2 infection induces DNA damage, through CHK1 degradation 897 and impaired 53BP1 recruitment, and cellular senescence. Nat. Cell Biol. 25, 550-564 (2023). 898 22. Im, J.-Y. et al. DDIAS promotes STAT3 activation by preventing STAT3 recruitment to 899 PTPRM in lung cancer cells. Oncogenesis 9, 1–11 (2020).

900 23. Im, J.-Y., Kang, M.-J., Kim, B.-K. & Won, M. DDIAS, DNA damage-induced apoptosis 901 suppressor, is a potential therapeutic target in cancer. Exp. Mol. Med. 1–7 (2023) 902 doi:10.1038/s12276-023-00974-6. 903 Angeli, F. et al. The spike effect of acute respiratory syndrome coronavirus 2 and 24. 904 coronavirus disease 2019 vaccines on blood pressure. Eur. J. Intern. Med. 109, 12–21 (2023). 905 25. Silva-Aguiar, R. P. et al. Role of the renin-angiotensin system in the development of 906 severe COVID-19 in hypertensive patients. Am. J. Physiol.-Lung Cell. Mol. Physiol. 319, L596-907 L602 (2020). 908 26. Li, Y. et al. The emerging role of ISWI chromatin remodeling complexes in cancer. J. 909 Exp. Clin. Cancer Res. 40, 346 (2021). 910 27. The Dendritic Cell Receptor for Endocytosis, Dec-205, Can Recycle and Enhance 911 Antigen Presentation via Major Histocompatibility Complex Class II-Positive Lysosomal Compartments | Journal of Cell Biology | Rockefeller University Press. 912 913 https://rupress.org/jcb/article/151/3/673/21295/The-Dendritic-Cell-Receptor-for-Endocytosis-914 Dec. 915 28. Sims, A. C. et al. Release of Severe Acute Respiratory Syndrome Coronavirus Nuclear 916 Import Block Enhances Host Transcription in Human Lung Cells. J. Virol. 87, 3885–3902 (2013). 917 29. A Network Integration Approach to Predict Conserved Regulators Related to 918 Pathogenicity of Influenza and SARS-CoV Respiratory Viruses | PLOS ONE. 919 https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0069374. 920 30. Gómez-Carballa, A. et al. A multi-tissue study of immune gene expression profiling 921 highlights the key role of the nasal epithelium in COVID-19 severity. Environ. Res. 210, 112890 922 (2022). 923 31. Policard, M., Jain, S., Rego, S. & Dakshanamurthy, S. Immune characterization and 924 profiles of SARS-CoV-2 infected patients reveals potential host therapeutic targets and SARS-925 CoV-2 oncogenesis mechanism. Virus Res. 301, 198464 (2021). 926 32. Wei, J. et al. Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2 927 Infection. Cell 184, 76-91.e13 (2021). 928 33. Wei, J. et al. Pharmacological disruption of mSWI/SNF complex activity restricts SARS-929 CoV-2 infection. Nat. Genet. 55, 471-483 (2023). 930 34. Pereira, A. C. et al. Genetic risk factors and COVID-19 severity in Brazil: results from 931 BRACOVID study. Hum. Mol. Genet. 31, 3021-3031 (2022). 932 35. Zhu, X. et al. ZBTB7A promotes virus-host homeostasis during human coronavirus 229E 933 infection. Cell Rep. 41, 111540 (2022). 934 36. Gupta, S. et al. Emerging role of ZBTB7A as an oncogenic driver and transcriptional 935 repressor. Cancer Lett. 483, 22-34 (2020). 936 37. Yoneyama, M. et al. Direct triggering of the type I interferon system by virus infection: 937 activation of a transcription factor complex containing IRF-3 and CBP/p300. EMBO J. 17, 1087-938 1095 (1998).

939 940	38. Yang, Q. <i>et al.</i> SARS-CoV-2 infection activates CREB/CBP in cellular cyclic AMP- dependent pathways. <i>J. Med. Virol.</i> 95 , e28383 (2023).
941 942 943	39. Harris, P. A. <i>et al.</i> Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. <i>J. Biomed. Inform.</i> 42 , 377–381 (2009).
944 945	40. Harris, P. A. <i>et al.</i> The REDCap consortium: Building an international community of software platform partners. <i>J. Biomed. Inform.</i> 95 , 103208 (2019).
946 947	41. Purcell, S. <i>et al.</i> PLINK: A Tool Set for Whole-Genome Association and Population- Based Linkage Analyses. <i>Am. J. Hum. Genet.</i> 81 , 559–575 (2007).
948 949	42. Alexander, D. H., Novembre, J. & Lange, K. Fast model-based estimation of ancestry in unrelated individuals. <i>Genome Res.</i> 19 , 1655–1664 (2009).
950 951	43. Auton, A. <i>et al.</i> A global reference for human genetic variation. <i>Nature</i> 526 , 68–74 (2015).
952 953	44. Mao, X. <i>et al</i> . A Genomewide Admixture Mapping Panel for Hispanic/Latino Populations. <i>Am. J. Hum. Genet.</i> 80 , 1171–1178 (2007).
954 955	45. Wojcik, G. L. <i>et al</i> . Genetic analyses of diverse populations improves discovery for complex traits. <i>Nature</i> 570 , 514–518 (2019).
956 957	46. Zheng, X. & Davis, J. W. SAIGEgds—an efficient statistical tool for large-scale PheWAS with mixed models. <i>Bioinformatics</i> 37 , 728–730 (2021).
958 959	47. Zhou, W. <i>et al.</i> Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. <i>Nat. Genet.</i> 50 , 1335–1341 (2018).
960 961	48. METAL: fast and efficient meta-analysis of genomewide association scans Bioinformatics Oxford Academic.
962	https://academic.oup.com/bioinformatics/article/26/17/2190/198154.
963 964	49. Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and annotation of genetic associations with FUMA. <i>Nat. Commun.</i> 8 , 1826 (2017).
965 966	50. MAGMA: Generalized Gene-Set Analysis of GWAS Data PLOS Computational Biology. https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1004219.
967 968	51. Giambartolomei, C. <i>et al.</i> Bayesian Test for Colocalisation between Pairs of Genetic Association Studies Using Summary Statistics. <i>PLOS Genet.</i> 10 , e1004383 (2014).
969 970	52. Wallace, C. Eliciting priors and relaxing the single causal variant assumption in colocalisation analyses. <i>PLOS Genet.</i> 16 , e1008720 (2020).
971 972 973	53. Kachuri, L. <i>et al.</i> Gene expression in African Americans, Puerto Ricans and Mexican Americans reveals ancestry-specific patterns of genetic architecture. <i>Nat. Genet.</i> 55 , 952–963 (2023).
974 975	54. Barbeira, A. N. <i>et al.</i> Exploiting the GTEx resources to decipher the mechanisms at GWAS loci. <i>Genome Biol.</i> 22 , 49 (2021).
976 977	55. Barbeira, A. N. <i>et al.</i> GWAS and GTEx QTL integration. (2019) doi:10.5281/zenodo.3518299.

978 979	56. Barbeira, A. N. <i>et al.</i> Exploring the phenotypic consequences of tissue specific gene expression variation inferred from GWAS summary statistics. <i>Nat. Commun.</i> 9 , 1825 (2018).
980 981	57. Barbeira, A. N. <i>et al.</i> Integrating predicted transcriptome from multiple tissues improves association detection. <i>PLOS Genet.</i> 15 , e1007889 (2019).
982 983 984	58. Genome-wide patterns of population structure and admixture among Hispanic/Latino populations PNAS. https://www.pnas.org/doi/10.1073/pnas.0914618107?url_ver=Z39.88-2003𝔯_id=ori:rid:crossref.org𝔯_dat=cr_pub%20%200pubmed.
985	

986

Variable	Non Hospitalized N = 1,887	Hospitalized N = 1,608
Age – mean years ± SD	39.1 ± 11.9	54.1 ±14.5
Sex - N (%)		
Female (%)	1253 (66.4)	668 (41.5)
GIA* – % mean ±SD		
European	54.4 ±16.2	39.4 ± 20.7
African	15.3 ± 12.7	9.1 ± 11.6
Native American	30.3 ± 19.8	51.46 ± 26.5
Comorbidities - N (%)		
Vascular/endocrinological	488 (25.9)	873 (54.3)
Cardiac	60 (3.2)	150 (9.3)
Nervous	15 (0.8)	61 (3.8)
Digestive	14 (0.7)	33 (2.0)
Onco-hematological	21 (1.1)	48 (3.00)
Respiratory	76 (4.0)	118 (7.3)

Table 1. Demographic characteristics of the SCOURGE Latin-American cohort. 987

988 *Global genetic inferred ancestry.

989

Table 2. Lead independent variants in the admixed AMR GWAS meta-analysis. 990

				OD (054(CD)		EAF	EAF	Nearest
SNP rsID	chr:pos	EA	NEA	OR (95% CI)	P-value	cases	controls	gene

rs13003835	2:159407982	Т	С	1.20 (1.12-1.27)	3.66E-08	0.563	0.429	BAZ2B
rs35731912	3:45848457	Т	С	1.65 (1.47-1.85)	6.30E-17	0.087	0.056	LZTFL1
rs2477820	6:41535254	А	Т	0.84 (0.79-0.89)	1.89E-08	0.453	0.517	FOXP4-AS1
rs77599934	11:82906875	G	А	2.27 (1.7-3.04)	2.26E-08	0.016	0.011	DDIAS

991 EA: effect allele; NEA: non-effect allele; EAF: effect allele frequency in the SCOURGE study.

992


- 993 Table 3. Novel variants in the SC-HGI_{ALL} and SC-HGI_{3POP} meta-analyses (with respect
- to HGIv7). Independent signals after LD clumping.

SNP rsID	chr:pos	EA	NEA	OR (95% CI)	P-value	Nearest gene	Analysis
rs76564172	16:3892266	Т	G	1.31 (1.19-1.44)	9.64E-09	CREBBP	SC-HGI _{3POP}
rs66833742	19:4063488	Т	С	0.94 (0.92-0.96)	1.89E-08	ZBTB7A	SC-HGI _{3POP}
rs66833742	19:4063488	Т	С	0.94 (0.92-0.96)	2.50E-08	ZBTB7A	SC-HGI _{ALL}
rs2876034	20:6492834	А	Т	0.95 (0.93-0.97)	2.83E-08	CASC20	SC-HGI _{ALL}

995 EA: effect allele; NEA: non-effect allele.

996

997 Figure 1. Flow chart of this study.




998

1000

1001


- 1002 Figure 2. A) Manhattan plot for the admixed AMR GWAS meta-analysis. Probability
- thresholds at $p=5x10^{-8}$ and $p=5x10^{-5}$ are indicated by the horizontal lines. Genome-wide
- significant associations with COVID-19 hospitalizations were found in chromosome 2
- 1005 (within BAZ2B), chromosome 3 (within LZTFL1), chromosome 6 (within FOXP4), and
- 1006 chromosome 11 (within DDIAS). A Quantile-Quantile plot is shown in supplementary
- 1007 Figure 2. B) Regional association plots for rs1003835 at chromosome 2 and rs77599934
- at chromosome 11; C) Allele frequency distribution across The 1000 Genomes Project
- 1009 populations for the lead variants rs1003835 and rs77599934.



1010


Figure 3. Forest plot showing effect sizes and the corresponding confidence intervals for the sentinel variants identified in the AMR meta-analysis across populations. All beta values with their corresponding CIs were retrieved from the B2 population-specific meta-analysis from the HGI v7 release, except for AMR, for which the beta value and IC from the HGI_{AMR}-SCOURGE meta-analysis is represented.

1017



1020 Figure 4. (A) Polygenic risk stratified by PGS deciles comparing each risk group 1021 against the lowest risk group (OR-95%CI); (B) Distribution of the PGS scores in each

1022 of the severity scale classes (0-Asymptomatic, 1-Mild disease, 2-Moderate disease, 3-



1023 Severe disease, 4-Critical disease).

1024

1025

1026

1027 Supplementary Material for: Novel risk loci for COVID-19 hospitalization among


1028 admixed American populations

- 1029 Supplementary Tables are provided in a separate excel file
- 1030 Supplementary figures


1031 Supplementary Figure 1. Global Genetic Inferred Ancestry (GIA) composition in

the SCOURGE Latin-American cohort. European (EUR), African (AFR) and Native
American (AMR) GIA was derived with ADMIXTURE from a reference panel
composed of Aymaran, Mayan, Nahuan, and Quechuan individuals of Native-American
genetic ancestry and randomly selected samples from the EUR and AFR 1KGP
populations. The colours represent the different geographical sampling regions from


1037 which the admixed American individuals from SCOURGE were recruited.



1040 Supplementary Figure 2. Quantile-Quantile plot for the AMR GWAS meta1041 analysis. A lambda inflation factor of 1.015 was obtained.



1045	
1046	
1047	
1048	
1049	
1050	
1051	
1052	
1053	
1054	Supplementary Figure 3. Regional association plots for the fine mapped loci in
1055	chromosomes 2 (upper panel) and 16 (lower panel). Coloured in red, the variants
1056	allocated to the credible set at the 95% confidence according to the Bayesian fine
1057	mapping. In blue, the sentinel variant.







1061 Supplementary Figure 4. Sensitivity plots from COLOC with expression data from


GTEx v8. The range of p12 values (probability that a SNP is associated with both traits) for which the rule $H_4>0.7$ is supported is shown in green in the right plots for each analysis. Plots in the left represent the variants included in the risk region common to both traits along their individual association $-\log 10$ (p-values) for each trait, whereas the shading shows the posterior probability that the SNP is causal given H_4 is true. Trait 1 corresponds to COVID-19 hospitalization, while trait 2 corresponds to gene expression in each analysis.

1069




LY75 in whole blood





1074


Supplementary Figure 5. Sensitivity plots from COLOC with whole blood 1075 expression data from the GALA and SAGE II studies in AMR individuals. AFRhp5 1076 1077 corresponds to the expression dataset computed in individuals with high African ancestries; AMRhp5 corresponds to the expression dataset computed individuals with 1078 high AMR ancestries; *pooled* corresponds to the dataset computed with the total of 1079 individuals from the study. In the right, the plots show in green the range of p12 values 1080 (probability that a SNP is associated with both traits) for which the rule $H_4>0.7$ is 1081 1082 supported. Plots in the left represent the variants included in the risk region common to 1083 both traits along their individual association -log10(p-values) for each trait, whereas the 1084 shading shows the posterior probability that the SNP is causal given H_4 is true. Trait 1 corresponds to COVID-19 hospitalization, while trait 2 corresponds to gene expression. 1085




CD302 in whole blood AFRhp5




BAZ2B in whole blood AFRhp5







1088

LY75 in whole blood AFRhp5






LY75 in whole blood AMRhp5



1093

1094

1095 Supplementary Figure 6. Gene-tissue pairs for which either rs1003835 or 1096 rs60606421 are significant eQTLs at FDR<0.05 (data retrieved from 1097 https://gtexportal.org/home/snp/). rs1003835 (chromosome 2) maps to *BAZ2B*, *LY75*, 1098 and *PLA2R* genes. As for the lead variant of chromosome 11, rs77599934, since it was 1099 not an eQTL, we used an LD proxy variant (rs60606421). *DDIAS* and *PRCP* genes map 1100 closely to this variant. NES and p-values correspond to the normalized effect size (and 1101 direction) of eQTL-gene associations and the p-value for the tissue, respectively.



1103

1104

1105 Scourge Cohort Group

1106 Full list of cohort members and affiliations

1107 Javier Abellan^{1,2}; René Acosta-Isaac³; Jose María Aguado^{4,5,6,7}; Carlos Aguilar⁸; Sergio

- 1108 Aguilera-Albesa^{9,10}; Abdolah Ahmadi Sabbagh¹¹; Jorge Alba¹²; Sergiu Albu^{13,14,15};
- 1109 Karla A.M. Alcalá-Gallardo¹⁶; Julia Alcoba-Florez¹⁷; Sergio Alcolea Batres¹⁸; Holmes
- 1110 Rafael Algarin-Lara^{19,20}; Virginia Almadana²¹; Julia Almeida^{22,23,24,25}; Berta
- 1111 Almoguera^{26,27}; María R. Alonso²⁸; Nuria Alvarez²⁸; Rodolfo Alvarez-Sala Walther¹⁸;
- 1112 Mónica T. Andrade^{29,30}; Álvaro Andreu-Bernabeu^{31,6}; Maria Rosa Antonijoan³²; Eunate

Arana-Arri^{33,34}; Carlos Aranda^{35,36}; Celso Arango^{31,37,6}; Carolina Araque^{38,39}; Nathalia 1113 K. Araujo⁴⁰; Izabel M.T. Araujo⁴¹; Ana C. Arcanjo^{42,43,44}; Ana Arnaiz^{45,46,47}; Francisco 1114 Arnalich Fernández⁴⁸; María J. Arranz⁴⁹; José Ramon Arribas Lopez⁴⁸; Maria-Jesus 1115 Artiga⁵⁰; Yubelly Avello-Malaver⁵¹; Carmen Ayuso^{26,27}; Ana Margarita Baldión⁵¹; 1116 Belén Ballina Martín¹¹; Raúl C. Baptista-Rosas^{52,53,54}; Andrea Barranco-Díaz²⁰; María 1117 Barreda- Sánchez^{55,56}; Viviana Barrera-Penagos⁵¹; Moncef Belhassen-Garcia^{57,58}; 1118 Enrique Bernal⁵⁵; David Bernal-Bello⁵⁹; Joao F. Bezerra⁶⁰; Marcos A.C. Bezerra⁶¹; 1119 Natalia Blanca-López⁶²; Rafael Blancas⁶³; Lucía Boix-Palop⁶⁴; Alberto Borobia⁶⁵; Elsa 1120 Bravo⁶⁶; María Brion^{67,68}; Óscar Brochado-Kith^{69,7}; Ramón Brugada^{70,71,68,72}; Matilde 1121 Bustos⁷³; Alfonso Cabello⁷⁴; Juan J. Caceres-Agra⁷⁵; Esther Calbo⁷⁶; Enrique J. 1122 Calderón^{77,78,79}; Shirley Camacho⁸⁰; Cristina Carbonell^{81,58}; Servando Cardona-1123 Huerta⁸²; Antonio Augusto F. Carioca⁸³; Maria Sanchez Carpintero^{35,36}; Carlos Carpio 1124 Segura¹⁸; Thássia M.T. Carratto⁸⁴; José Antonio Carrillo-Avila⁸⁵; Maria C.C. 1125 Carvalho⁸⁶; Carlos Casasnovas^{87,88,27}; Luis Castano^{33,34,27,89,90}; Carlos F. Castaño^{35,36}; 1126 Jose E. Castelao⁹¹; Aranzazu Castellano Candalija⁹²; María A. Castillo⁸⁰; Yolanda 1127 Cañadas³⁶; Francisco C. Ceballos²⁷; Jessica G. Chaux³⁹; Walter G. Chaves-1128 Santiago^{93,39}; Sylena Chiquillo-Gómez^{19,20}; Marco A. Cid-Lopez¹⁶; Oscar Cienfuegos-1129 Jimenez⁸²; Rosa Conde-Vicente⁹⁴; M. Lourdes Cordero-Lorenzana⁹⁵; Dolores 1130 Corella^{96,97}; Almudena Corrales^{98,99}; Jose L. Cortes-Sanchez^{82,100}; Marta Corton^{26,27}; 1131 Tatiana X. Costa¹⁰¹; Raquel Cruz^{27,102}; Marina S. Cruz⁴⁰; Luisa Cuesta¹⁰³; Gabriela C.R. 1132 Cunha¹⁰⁴; David Dalmau^{105,76}; Raquel C.S. Dantas-Komatsu⁴⁰; M. Teresa Darnaude¹⁰⁶; 1133 Alba De Martino-Rodríguez^{107,108}; Juan De la Cruz Troca^{109,110,78}; Juan Delgado-1134 Cuesta¹¹¹; Aranzazu Diaz de Bustamante¹⁰⁶; Covadonga M. Diaz-Caneja^{31,37,6}; Beatriz 1135 Dietl⁷⁶; Silvia Diz-de Almeida^{27,102}; Elena Domínguez-Garrido¹¹²; Alice M. Duarte⁴¹; 1136 Anderson Díaz-Pérez²⁰; Jose Echave-Sustaeta¹¹³; Rocío Eiros¹¹⁴; César O. Enciso-1137 Olivera^{38,39}; Gabriela Escudero¹¹⁵; Pedro Pablo España¹¹⁶; Gladys Mercedes Estigarribia 1138 Sanabria¹¹⁷; María Carmen Fariñas^{45,46,47}; Marianne R. Fernandes^{118,119}; Lidia 1139 Fernandez-Caballero^{26,27}; María J. Fernandez-Nestosa¹²⁰; Ramón Fernández^{45,121}; Silvia 1140 Fernández Ferrero¹¹; Yolanda Fernández Martínez¹¹; Ana Fernández-Cruz¹²²; Uxía 1141 Fernández-Robelo¹²³; Amanda Fernández-Rodríguez^{69,7}; Marta Fernández-1142 Sampedro^{45,47,46}; Ruth Fernández-Sánchez^{26,27}; Tania Fernández-Villa^{124,78}; Carmen 1143 Fernéndez Capitán⁹²; Patricia Flores-Pérez¹²⁵; Vicente Friaza^{78,79}; Lácides Fuenmayor-1144 Hernández²⁰; Marta Fuertes Núñez¹¹; Victoria Fumadó¹²⁶; Ignacio Gadea¹²⁷; Lidia 1145 Gagliardi^{35,36}; Manuela Gago-Domínguez^{128,129}; Natalia Gallego¹³⁰; Cristina Galoppo¹³¹; 1146 Carlos Garcia-Cerrada^{1,2,132}; Josefina Garcia-García⁵⁵; Inés García^{26,27}; Mercedes 1147 García^{35,36}; Leticia García^{35,36}; María Carmen García Torrejón^{133,2}; Irene García-1148 García⁶⁵; Carmen García-Ibarbia^{45,47,46}; Andrés C. García-Montero¹³⁴; Ana García-1149 Soidán¹³⁵; Elisa García-Vázquez⁵⁵; Aitor García-de-Vicuña^{33,136}; Emiliano Garza-1150 Frias⁸²; Jesus Gaytán-Martínez¹³⁷, Angela Gentile¹³¹; Belén Gil-Fournier¹³⁸; Fernan 1151 Gonzalez Bernaldo de Quirós¹³⁹; Manuel Gonzalez-Sagrado⁹⁴; Hugo Gonzalo Benito¹⁴⁰; 1152 Beatriz González Álvarez^{107,108}; Anna González-Neira²⁸; Javier González-Peñas^{31,6,37}; 1153 Oscar Gorgojo-Galindo¹⁴¹; Florencia Guaragna¹³¹; Genilson P. Guegel¹⁴²; Beatriz 1154 Guillen-Guio⁹⁸; Encarna Guillen-Navarro^{55,143,144,27}; Pablo Guisado-Vasco¹¹³; Luz D. 1155 Gutierrez-Castañeda^{145,39}; Juan F. Gutiérrez-Bautista¹⁴⁶; Luis Gómez Carrera¹⁸; María 1156

Gómez García¹²⁸; Ángela Gómez Sacristán¹⁴⁷; Javier Gómez-Arrue^{107,108}; Mario 1157 Gómez-Duque^{93,39}; Miguel Górgolas⁷⁴; Sarah Heili-Frades¹⁴⁸; Estefania Hernandez¹⁴⁹; 1158 Luis D. Hernandez-Ortega^{150,151}; Cristina Hernández Moro¹¹; Guillermo Hernández-1159 Pérez⁸¹; Rebeca Hernández-Vaquero¹⁵²; Belen Herraez²⁸; M. Teresa Herranz⁵⁵; María 1160 Herrera^{35,36}; María José Herrero^{153,154}; Antonio Herrero-Gonzalez¹⁵⁵; Juan P. 1161 Horcajada^{156,157,14,158,7}; Natale Imaz-Ayo³³; Maider Intxausti-Urrutibeaskoa¹⁵⁹; Rafael H. 1162 Jacomo¹⁶⁰; Rubén Jara⁵⁵; Perez Maria Jazmin¹³¹; María A. Jimenez-Sousa^{69,7}; Ángel 1163 Jiménez^{35,36}; Pilar Jiménez¹⁴⁶; Ignacio Jiménez-Alfaro¹⁶¹; Iolanda Jordan^{162,163,78}; Rocío 1164 Laguna-Goya^{164,165}; Daniel Laorden¹⁸; María Lasa-Lazaro^{164,165}; María Claudia 1165 Lattig^{80,166}; Ailen Lauriente¹³¹; Anabel Liger Borja¹⁶⁷; Lucía Llanos¹⁶⁹; Esther Lopez-1166 Garcia^{109,110,78,170}; Rosario Lopez-Rodriguez^{26,27}; Leonardo Lorente¹⁷¹; José E. 1167 Lozano¹⁷²; María Lozano-Espinosa¹⁶⁷; Andre D. Luchessi¹⁷³; Eduardo López 1168 Granados^{174,175,27}; Amparo López-Bernús^{81,58}; Miguel A. López-Ruz^{176,177,178}; Aluísio X. 1169 Magalhães-Brasil¹⁷⁹;Ignacio Mahillo^{180,181,99}; Esther Mancebo^{164,165}; Carmen Mar¹¹⁶; 1170 Cristina Marcelo Calvo⁹²; Miguel Marcos^{81,58}; Alba Marcos-Delgado¹²⁴; Pablo Mariscal 1171 Aguilar¹⁸; Marta Martin-Fernandez¹⁸²; Laura Martin-Pedraza⁶²; Amalia Martinez¹⁸³; 1172 Iciar Martinez-Lopez^{184,185}; Oscar Martinez-Nieto^{51,166}; Pedro Martinez-Paz¹⁴⁰; Angel 1173 Martinez-Perez¹⁸⁶; Michel F. Martinez-Resendez⁸²; María M. Martín¹⁸⁷; María Dolores 1174 Martín¹⁸⁸; Vicente Martín^{124,78}; Caridad Martín-López¹⁶⁷; José-Ángel Martín-1175 Oterino^{81,58}; María Martín-Vicente⁶⁹; Ricardo Martínez¹⁴⁹; Juan José Martínez^{88,27}; 1176 Silvia Martínez^{45,47}; Violeta Martínez Robles¹¹; Eleno Martínez-Aquino¹⁸⁹; Óscar 1177 Martínez-González¹⁹⁰; Andrea Martínez-Ramas^{26,27}; Laura Marzal^{26,27}; Alicia Marín 1178 Candon⁶⁵; Jose Antonio Mata-Marin,¹³⁷ Juliana F. Mazzeu^{179,191,192}; Jeane F.P. 1179 Medeiros⁴⁰; Francisco J. Medrano^{77,78,79}; Xose M. Meijome^{193,194}; Natalia Mejuto-1180 Montero¹⁹⁵; Celso T. Mendes-Junior^{84,196,197}; Humberto Mendoza Charris^{66,20}; Eleuterio 1181 Merayo Macías¹⁹⁸; Fátima Mercadillo¹⁹⁹; Arieh R. Mercado-Sesma^{150,151}; Pablo 1182 Minguez^{26,27}; Antonio J J. Molina^{124,78}; Elena Molina-Roldán²⁰⁰; Juan José Montoya¹⁴⁹; 1183 Patricia Moreira-Escriche²⁰¹; Xenia Morelos-Arnedo^{66,20}; Victor Moreno Cuerda^{1,2}; 1184 Alberto Moreno Fernández⁹²; Antonio Moreno-Docón⁵⁵; Junior Moreno-Escalante²⁰; 1185 Rubén Morilla^{79,202}; Patricia Muñoz García^{203,99,6}; Ana Méndez-Echevarria²⁰⁴; Pablo 1186 Neira¹³¹; Julian Nevado^{27,131,205}; Israel Nieto-Gañán¹³⁵; Joana F.R. Nunes⁴²; Rocio 1187 Nuñez- Torres²⁸; Antònia Obrador-Hevia^{206,207}; J. Gonzalo Ocejo-Vinyals^{45,47}; Virginia Olivar¹³¹; Silviene F. Oliveira^{179,208,208,210,211}; Lorena Ondo^{26,27}; Alberto Orfao^{22,23,24,25}; 1188 1189 Luis Ortega²¹²; Eva Ortega-Paino⁵⁰; Fernando Ortiz-Flores^{45,47}; Rocio Ortiz-Lopez^{213,82}; 1190 José A. Oteo^{12,214}; Harry Pachajoa^{215,216}; Manuel Pacheco¹⁴⁹; Fredy Javier Pacheco-1191 Miranda²⁰; Irene Padilla Conejo¹¹; Sonia Panadero-Fajardo⁸⁵; Mara Parellada^{31,37,6}; 1192 Roberto Pariente-Rodríguez¹³¹; Estela Paz-Artal^{164,165,217}; Germán Peces-Barba^{218,99}; 1193 Miguel S. Pedromingo Kus²¹⁹; Celia Perales¹²⁷; Patricia Perez²²⁰; Gustavo Perez-de-1194 Nanclares^{33,221}; Teresa Perucho²²²; Aline Pic-Taylor^{42,208,209,211}, Lisbeth A. Pichardo¹¹; 1195 Mel·lina Pinsach-Abuin^{70,68}; Luz Adriana Pinzón^{93,39}; Guillermo Pita³⁰; Francesc Pla-1196 Junca^{223,27}; Laura Planas-Serra^{88,27}; Ericka N. Pompa-Mera^{224,137}; Gloria L. Porras-1197 Hurtado¹⁴⁹; Aurora Pujol^{88,27,225}; César Pérez²²⁶; Felipe Pérez-García^{227,228}; Patricia 1198 Pérez-Matute²¹⁴; Alexandra Pérez-Serra^{70,68}; M. Elena Pérez-Tomás⁵⁵; María Eugenia 1199 Quevedo Chávez^{19,20}; Maria Angeles Quijada^{30,229}; Inés Quintela¹²⁸; Diana Ramirez-1200

Montaño²³⁰; Soraya Ramiro León¹³¹; Pedro Rascado Sedes²³¹; Delia Recalde^{107,108}; 1201 Emma Recio-Fernández²¹⁴; Salvador Resino^{69,7}; Adriana P. Ribeiro^{29,30,232}; Carlos S. 1202 Rivadeneira-Chamorro³⁹; Diana Roa-Agudelo⁵¹; Montserrat Robelo Pardo²³¹; Marilyn 1203 Johanna Rodriguez³⁹; German Ezequiel Rodriguez Novoa¹³¹; Fernando Rodriguez-1204 Artalejo^{109,110,78,170}; Carlos Rodriguez-Gallego^{233,234}; José A. Rodriguez-Garcia¹¹; María 1205 A. Rodriguez-Hernandez⁷³; Antonio Rodriguez-Nicolas¹⁴⁶; Agustí Rodriguez-1206 Palmero^{235,88}; Paula A. Rodriguez-Urrego⁵¹; Belén Rodríguez Maya¹; Marena 1207 Rodríguez-Ferrer²⁰; Emilio Rodríguez-Ruiz^{231,129}; Federico Rojo^{236,25}; Andrea Romero-1208 Coronado²⁰; Filomeno Rondón García¹¹; Lidia S. Rosa²³⁶; Antonio Rosales-Castillo²³⁷; 1209 Cladelis Rubio^{238,239}; María Rubio Olivera^{35,36}; Montserrat Ruiz^{88,27}; Francisco Ruiz-1210 Cabello^{146,177,240}; Eva Ruiz-Casares²²²; Juan J. Ruiz-Cubillan^{45,47}; Javier Ruiz-1211 Hornillos^{241,36,242}; Pablo Ryan^{243,244,245,7}; Hector D. Salamanca^{38,39}; Lorena Salazar-1212 García⁸⁰; Giorgina Gabriela Salgueiro Origlia⁹²; Cristina Sancho-Sainz¹⁵⁹; Jorge Luis 1213 Sandoval-Ramírez,¹³⁷ Anna Sangil⁶⁴; Arnoldo Santos²²⁶; Ney P.C. Santos¹¹⁸; Amanda 1214 C.M. Saúde ^{30,246} Agatha Schlüter^{88,27}; Sonia Segovia^{223,247,248}; Alex Serra-Llovich²⁴⁹; 1215 Fernando Sevil Puras⁸; Marta Sevilla Porras^{27,130}; Miguel A. Sicolo^{250,251}; Vivian N. 1216 Silbiger¹⁷³; Nayara S. Silva²⁵²; Fabiola T.C. Silva⁴⁰; Cristina Silván Fuentes²⁷; Jordi 1217 Solé-Violán^{253,99,254}; José Manuel Soria¹⁸⁶; Jose V. Sorlí^{96,97}; Renata R. Sousa¹⁷⁹; Juan 1218 Carlos Souto³; Karla S.C. Souza⁸⁶; Vanessa S. Souza¹⁰⁴; John J. Sprockel^{93,39}; David A. 1219 Suarez-Zamora⁵¹; José Javier Suárez-Rama¹²⁸; Pedro-Luis Sánchez^{114,58}; Antonio J. 1220 Sánchez López²⁵⁵; María Concepción Sánchez Prados¹⁸; Javier Sánchez Real¹¹; Jorge 1221 Sánchez Redondo^{1,256}; Clara Sánchez-Pablo¹¹⁴; Olga Sánchez-Pernaute²⁵⁷; Xiana 1222 Taboada-Fraga¹⁹⁵; Eduardo Tamayo^{258,140,7}; Alvaro Tamayo-Velasco²⁵⁹; Juan Carlos 1223 Taracido-Fernandez¹⁵⁵; Nathali A.C. Tavares²⁶⁰; Carlos Tellería^{107,108}; Jair Antonio 1224 Tenorio Castaño^{27,130,205}; Alejandro Teper¹³¹; Ronald P. Torres Gutiérrez²²¹; Juan 1225 Torres-Macho²⁶¹; Lilian Torres-Tobar³⁹; Jesús Troya²⁴³; Miguel Urioste¹⁹⁹; Juan 1226 Valencia-Ramos²⁶²; Agustín Valido^{21,263}; Juan Pablo Vargas Gallo^{264,265}; Belén 1227 Varón²⁶⁶; Romero H.T. Vasconcelos²⁶⁰; Tomas Vega²⁶⁷; Santiago Velasco-Quirce²⁶⁸; 1228 Julia Vidán Estévez¹¹; Miriam Vieitez-Santiago^{45,47}; Carlos Vilches²⁶⁹; Lavinia 1229 Villalobos¹¹; Felipe Villar²¹⁸; Judit Villar-Garcia^{270,271,272}; Cristina Villaverde^{26,27}; Pablo 1230 Villoslada-Blanco²¹⁴; Ana Virseda-Berdices⁶⁹; Valentina Vélez-Santamaría^{87,88}; 1231 Virginia Víctor^{35,36}; Zuleima Yáñez²⁰; Antonio Zapatero-Gaviria²⁷³; Ruth Zarate²⁷⁴; 1232 Sandra Zazo²³⁶; Gabriela V. da Silva⁴¹; Raimundo de Andrés²⁷⁵; Jéssica N.G. de 1233 Araújo²⁵²; Carmen de Juan²⁰¹; Julianna Lys de Sousa Alves Neri²⁷⁶; Carmen de la 1234 Horra⁷⁹; Ana B. de la Hoz³³; Victor del Campo-Pérez²⁷⁷; Manoella do Monte 1235 Alves^{278,279}; Katiusse A. dos Santos⁸⁶; Yady Álvarez-Benítez^{19,20}; Felipe Álvarez-1236 Navia^{81,58}; María Íñiguez²¹⁴; Miguel López de Heredia²⁷; Ingrid Mendes²⁷; Rocío 1237 Moreno²⁷; Esther Sande^{27,129,102}; Carlos Flores^{280,98,99,234}; José A. Riancho^{45,46,47,27}; 1238 Augusto Rojas-Martinez⁸²; Pablo Lapunzina^{27,130,205}; Angel Carracedo^{27,129,102,128} 1239

1240 Scourge Cohort Group's filiations

1241¹, Hospital Universitario Mostoles, Medicina Interna, Madrid, Spain

1242 ², Universidad Francisco de Vitoria, Madrid, Spain

1243 1244	³ , Haemostasis and Thrombosis Unit, Hospital de la Santa Creu i Sant Pau, IIB Sant Pau, Barcelona, Spain
1245 1246	⁴ , Unit of Infectious Diseases, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain
1247 1248	⁵ , Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0002), Instituto de Salud Carlos III, Madrid, Spain
1249	⁶ , School of Medicine, Universidad Complutense, Madrid, Spain
1250 1251	⁷ , Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain
1252	⁸ , Hospital General Santa Bárbara de Soria, Soria, Spain
1253 1254	⁹ , Pediatric Neurology Unit, Department of Pediatrics, Navarra Health Service Hospital, Pamplona, Spain
1255	¹⁰ , Navarra Health Service, NavarraBioMed Research Group, Pamplona, Spain
1256	¹¹ , Complejo Asistencial Universitario de León, León, Spain
1257	¹² , Hospital Universitario San Pedro, Infectious Diseases Department, Logroño, Spain
1258 1259	¹³ , Fundación Institut Guttmann, Institut Universitari de Neurorehabilitació adscrit a la UAB, Hospital de Neurorehabilitació, Barcelona, Spain
1260	¹⁴ , Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
1261 1262	¹⁵ , Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, Barcelona, Spain
1263	¹⁶ , Hospital General de Occidente, Guadalajara, Mexico
1264 1265	¹⁷ , Microbiology Unit, Hospital Universitario N. S. de Candelaria, Santa Cruz de Tenerife, Spain
1266	¹⁸ , Hospital Universitario La Paz-IDIPAZ, Servicio de Neumología, Madrid, Spain
1267	¹⁹ , Camino Universitario Adelita de Char, Mired IPS, Barranquilla, Colombia
1268	²⁰ , Universidad Simón Bolívar, Facultad de Ciencias de la Salud, Barranquilla, Colombia
1269	²¹ , Hospital Universitario Virgen Macarena, Neumología, Seville, Spain
1270	²² , Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain
1271 1272	²³ , Centro de Investigación del Cáncer (IBMCC) Universidad de Salamanca - CSIC, Salamanca, Spain
1273	²⁴ , Biomedical Research Institute of Salamanca (IBSAL) Salamanca, Spain
1274 1275	²⁵ , Centre for Biomedical Network Research on Cancer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain
1276 1277	²⁶ , Department of Genetics & Genomics, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital - Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
1278 1279	²⁷ , Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain
1280	²⁸ , Spanish National Cancer Research Centre, Human Genotyping-CEGEN Unit, Madrid, Spain
1281	²⁹ , Hospital das Forças Armadas, Brazil

1282	³⁰ , Exército Brasileiro, Brazil
1283 1284	³¹ , Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón (IISGM), Madrid, Spain
1285 1286	³² , Clinical Pharmacology Service, Hospital de la Santa Creu i Sant Pau, IIB Sant Pau, Barcelona, Spain
1287	³³ , Biocruces Bizkai HRI, Barakaldo, Bizkaia, Spain
1288	³⁴ , Cruces University Hospital, Osakidetza, Barakaldo, Bizkaia, Spain
1289	³⁵ , Hospital Infanta Elena, Valdemoro, Madrid, Spain
1290 1291	³⁶ , Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital - Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
1292 1293	³⁷ , Centre for Biomedical Network Research on Mental Health (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain
1294	³⁸ , Fundación Hospital Infantil Universitario de San José, Bogotá, Colombia
1295	³⁹ , Fundación Universitaria de Ciencias de la Salud, Bogotá, Colombia
1296 1297	⁴⁰ , Universidade Federal do Rio Grande do Norte, Programa de Pós-graduação em Ciências da Saúde, Natal, Brazil
1298 1299	⁴¹ , Universidade Federal do Rio Grande do Norte, Departamento de Medicina Clínica, Natal, Brazil
1300 1301	⁴² , Departamento de Genética e Morfologia, Instituto de Ciências Biológicas, Universidade de Brasília, Brasilia, Brazil
1302	⁴³ , Colégio Marista de Brasilia, Brazil
1303	⁴⁴ , Associação Brasileira de Educação e Cultura, Brazil
1304	⁴⁵ , IDIVAL, Santander, Spain
1305	⁴⁶ , Universidad de Cantabria, Santander, Spain
1306	⁴⁷ , Hospital U M Valdecilla, Santander, Spain
1307	⁴⁸ , Hospital Universitario La Paz-IDIPAZ, Servicio de Medicina Interna, Madrid, Spain
1308	⁴⁹ , Fundació Docència I Recerca Mutua Terrassa, Barcelona, Spain
1309	⁵⁰ , Spanish National Cancer Research Center, CNIO Biobank, Madrid, Spain
1310	⁵¹ , Fundación Santa Fe de Bogota, Departamento Patologia y Laboratorios, Bogotá, Colombia
1311	⁵² , Hospital General de Occidente, Zapopan, Jalisco, Mexico
1312	⁵³ , Centro Universitario de Tonalá, Universidad de Guadalajara, Tonalá, Jalisco, Mexico
1313 1314	⁵⁴ , Centro de Investigación Multidisciplinario en Salud, Universidad de Guadalajara, Tonalá, Jalisco, Mexico
1315	⁵⁵ , Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), Murcia, Spain
1316	⁵⁶ , Universidad Católica San Antonio de Murcia (UCAM), Murcia, Spain
1317 1318	⁵⁷ , Hospital Universitario de Salamanca-IBSAL, Servicio de Medicina Interna-Unidad de Enfermedades Infecciosas, Salamanca, Spain
1319	⁵⁸ , Universidad de Salamanca, Salamanca, Spain

1320	⁵⁹ , Hospital Universitario de Fuenlabrada, Department of Internal Medicine, Madrid, Spain
1321	⁶⁰ , Escola Tecnica de Saúde, Laboratorio de Vigilancia Molecular Aplicada, Pará, Brazil
1322	⁶¹ , Federal University of Pernambuco, Genetics Postgraduate Program, Recife, PE, Brazil
1323	⁶² , Hospital Universitario Infanta Leonor, Servicio de Alergia, Madrid, Spain
1324	⁶³ , Hospital Universitario del Tajo, Servicio de Medicina Intensiva, Aranjuez, Spain
1325	⁶⁴ , Hospital Universitario Mutua Terrassa, Barcelona, Spain
1326	⁶⁵ , Hospital Universitario La Paz-IDIPAZ, Servicio de Farmacología, Madrid, Spain
1327	⁶⁶ , Alcaldía de Barranquilla, Secretaría de Salud, Barranquilla, Colombia
1328 1329	⁶⁷ , Instituto de Investigación Sanitaria de Santiago (IDIS), Xenética Cardiovascular, Santiago de Compostela, Spain
1330 1331	⁶⁸ , Centre for Biomedical Network Research on Cardiovascular Diseases (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain
1332 1333	⁶⁹ , Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología (CNM), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
1334 1335	⁷⁰ , Cardiovascular Genetics Center, Institut d'Investigació Biomèdica Girona (IDIBGI), Girona, Spain
1336	⁷¹ , Medical Science Department, School of Medicine, University of Girona, Girona, Spain
1337	⁷² , Hospital Josep Trueta, Cardiology Service, Girona, Spain
1338 1339	⁷³, Institute of Biomedicine of Seville (IBiS), Consejo Superior de Investigaciones Científicas (CSIC)- University of Seville- Virgen del Rocio University Hospital, Seville, Spain
1340 1341	⁷⁴ , Division of Infectious Diseases, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital - Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
1342 1343	⁷⁵ , Intensive Care Unit, Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain
1344	⁷⁶ , Hospital Universitario Mutua Terrassa, Terrassa, Spain
1345 1346	⁷⁷ , Departamento de Medicina, Hospital Universitario Virgen del Rocío,Universidad de Sevilla, Seville, Spain
1347 1348	⁷⁸ , Centre for Biomedical Network Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
1349 1350	⁷⁹ , Institute of Biomedicine of Seville (IBiS), Consejo Superior de Investigaciones Científicas (CSIC)- University of Seville- Virgen del Rocio University Hospital, Seville, Spain
1351	⁸⁰ , Universidad de los Andes, Facultad de Ciencias, Bogotá, Colombia
1352 1353	⁸¹ , Hospital Universitario de Salamanca-IBSAL, Servicio de Medicina Interna, Salamanca, Spain
1354 1355	⁸² , Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud and Hospital San Jose TecSalud, Monterrey, Mexico
1356	⁸³ , University of Fortaleza (UNIFOR), Department of Nutrition. Fortaleza, Brazil
1357 1358	⁸⁴ , Departamento de Química, Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto, Universidade de São Paulo, Brazil

	95
1359	⁸⁵ , Andalusian Public Health System Biobank, Granada, Spain
1360 1361	⁸⁶ , Universidade Federal do Rio Grande do Norte, Programa de Pós-Graduação em Ciências Farmacêuticas, Natal, Brazil
1362 1363	⁸⁷ , Neuromuscular Unit, Neurology Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat (Barcelona), Spain
1364 1365	⁸⁸ , Bellvitge Biomedical Research Institute (IDIBELL), Neurometabolic Diseases Laboratory, L'Hospitalet de Llobregat, Spain
1366 1367	⁸⁹ , Centre for Biomedical Network Research on Diabetes and Metabolic Associated Diseases (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain
1368	⁹⁰ , University of Pais Vasco, UPV/EHU, Bizkaia, Spain
1369 1370	⁹¹ , Oncology and Genetics Unit, Instituto de Investigacion Sanitaria Galicia Sur, Xerencia de Xestion Integrada de Vigo-Servizo Galego de Saúde, Vigo, Spain
1371	⁹² , Hospital Universitario La Paz, Hospital Carlos III, Madrid, Spain
1372	⁹³ , Hospital de San José, Sociedad de Cirugía de Bogota, Bogotá, Colombia
1373	⁹⁴ , Hospital Universitario Río Hortega, Valladolid, Spain
1374 1375	⁹⁵ , Servicio de Medicina intensiva, Complejo Hospitalario Universitario de A Coruña (CHUAC), Sistema Galego de Saúde (SERGAS), A Coruña, Spain
1376	⁹⁶ , Valencia University, Preventive Medicine Department, Valencia, Spain
1377 1378	⁹⁷ , Centre for Biomedical Network Research on Physiopatology of Obesity and Nutrition (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
1379	⁹⁸ , Research Unit, Hospital Universitario N.S. de Candelaria, Santa Cruz de Tenerife, Spain
1380 1381	⁹⁹ , Centre for Biomedical Network Research on Respiratory Diseases (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
1382 1383	¹⁰⁰ , Otto von Guericke University, Departament of Microgravity and Translational Regenerative Medicine, Magdeburg, Germany
1384	¹⁰¹ , Maternidade Escola Janário Cicco, Natal, Brazil
1385 1386	¹⁰² , Centro Singular de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain
1387 1388	¹⁰³ , Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón (IiSGM), Madrid, Spain
1389 1390	¹⁰⁴ , Programa de Pós Graduação em Ciências da Saúde, Faculdade de Medicina, Universidade de Brasília, Brasilia, Brazil
1391	¹⁰⁵ , Fundació Docència I Recerca Mutua Terrassa, Terrassa, Spain
1392	¹⁰⁶ , Hospital Universitario Mostoles, Unidad de Genética, Madrid, Spain
1393	¹⁰⁷ , Instituto Aragonés de Ciencias de la Salud (IACS), Zaragoza, Spain
1394	¹⁰⁸ , Instituto Investigación Sanitaria Aragón (IIS-Aragon), Zaragoza, Spain
1395 1396	¹⁰⁹ , Department of Preventive Medicine and Public Health, School of Medicine, Universidad Autónoma de Madrid, Madrid, Spain
1397	¹¹⁰ , IdiPaz (Instituto de Investigación Sanitaria Hospital Universitario La Paz), Madrid, Spain

1398	¹¹¹ , Hospital Universitario Virgen del Rocío, Servicio de Medicina Interna, Seville, Spain
1399	¹¹² , Unidad Diagnóstico Molecular. Fundación Rioja Salud, La Rioja, Spain
1400	¹¹³ , Hospital Universitario Quironsalud Madrid, Madrid, Spain
1401	¹¹⁴ , Hospital Universitario de Salamanca-IBSAL, Servicio de Cardiología, Salamanca, Spain
1402	¹¹⁵ , Hospital Universitario Puerta de Hierro, Servicio de Medicina Interna, Majadahonda, Spain
1403 1404	¹¹⁶ , Biocruces Bizkaia Health Research Institute, Galdakao University Hospital, Osakidetza, Bizkaia, Spain
1405 1406	¹¹⁷ , Instituto Regional de Investigación en Salud-Universidad Nacional de Caaguazú, Caaguazú, Paraguay
1407	¹¹⁸ , Universidade Federal do Pará, Núcleo de Pesquisas em Oncologia, Belém, Pará, Brazil
1408	¹¹⁹ , Hospital Ophir Loyola, Departamento de Ensino e Pesquisa, Belém, Pará, Brazil
1409	¹²⁰ , Universidad Nacional de Asunción, Facultad de Politécnica, Paraguay
1410	¹²¹ , Fundación Asilo San Jose, Santander, Spain
1411 1412 1413	¹²² , Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital Universitario Puerta de Hierro, Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana, Madrid, Spain
1414 1415	¹²³ , Urgencias Hospitalarias, Complejo Hospitalario Universitario de A Coruña (CHUAC), Sistema Galego de Saúde (SERGAS), A Coruña, Spain
1416 1417	¹²⁴ , Grupo de Investigación en Interacciones Gen-Ambiente y Salud (GIIGAS) - Instituto de Biomedicina (IBIOMED), Universidad de León, León, Spain
1418	¹²⁵ , Hospital Universitario Niño Jesús, Pediatrics Department, Madrid, Spain
1419 1420	¹²⁶ , Unitat de Malalties Infeccioses i Importades, Servei de Pediatría, Infectious and Imported Diseases, Pediatric Unit, Hospital Universitari Sant Joan de Deú, Barcelona, Spain
1421 1422	¹²⁷ , Microbiology Department, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital - Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
1423 1424	¹²⁸, Fundación Pública Galega de Medicina Xenómica, Sistema Galego de Saúde (SERGAS)Santiago de Compostela, Spain
1425	¹²⁹ , Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Spain
1426 1427	¹³⁰ , Instituto de Genética Médica y Molecular (INGEMM), Hospital Universitario La Paz- IDIPAZ, Madrid, Spain
1428	¹³¹ , Hospital de Niños Ricardo Gutierrez, Buenos Aires, Argentina
1429 1430	¹³² , Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain Universidad Francisco de Vitoria, Madrid,Spain
1431	¹³³ , Hospital Infanta Elena, Servicio de Medicina Intensiva, Valdemoro, Madrid, Spain
1432 1433	¹³⁴ , University of Salamanca, Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain
1434	¹³⁵ , Department of Immunology, IRYCIS, Hospital Universitario Ramón y Cajal, Madrid, Spain
1435	¹³⁶ , Osakidetza, Cruces University Hospital, Bizkaia, Spain

¹³⁷, Instituto Mexicano del Seguro Social, IMSS. Centro Médico Nacional La Raza. Hospital de 1436 Infectología. Mexico City, Mexico. 1437 ¹³⁸, Hospital Universitario de Getafe, Servicio de Genética, Madrid, Spain 1438 ¹³⁹, Ministerio de Salud Ciudad de Buenos Aires, Buenos Aires, Argentina 1439 ¹⁴⁰, Hospital Clinico Universitario de Valladolid, Unidad de Apovo a la Investigación, 1440 1441 Valladolid, Spain 1442 ¹⁴¹, Universidad de Valladolid, Departamento de Cirugía, Valladolid, Spain ¹⁴², Secretaria Municipal de Saude de Apodi, Natal, Brazil 1443 ¹⁴³, Sección Genética Médica - Servicio de Pediatría, Hospital Clínico Universitario Virgen de la 1444 Arrixaca, Servicio Murciano de Salud, Murcia, Spain 1445 ¹⁴⁴, Departamento Cirugía, Pediatría, Obstetricia y Ginecología, Facultad de Medicina, 1446 Universidad de Murcia (UMU), Murcia, Spain 1447 ¹⁴⁵, Hospital Universitario Centro Dermatológico Federico Lleras Acosta, Bogotá, Colombia 1448 ¹⁴⁶. Hospital Universitario Virgen de las Nieves, Servicio de Análisis Clínicos e Inmunología. 1449 Granada, Spain 1450 ¹⁴⁷, Pneumology Department, Hospital General Universitario Gregorio Marañón (iiSGM), 1451 Madrid, Spain 1452 ¹⁴⁸, Intermediate Respiratory Care Unit, Department of Pneumology, Instituto de Investigación 1453 Sanitaria-Fundación Jiménez Díaz University Hospital - Universidad Autónoma de Madrid (IIS-1454 1455 FJD, UAM), Madrid, Spain ¹⁴⁸, Clinica Comfamiliar Risaralda, Pereira, Colombia 1456 ¹⁵⁰, Centro Universitario de Tonalá, Universidad de Guadalajara, Guadalajara, Mexico 1457 ¹⁵¹, Centro de Investigación Multidisciplinario en Salud, Universidad de Guadalajara, 1458 1459 Guadalajara, Mexico ¹⁵², Unidad de Cuidados, Intensivos Hospital Clínico Universitario de Santiago (CHUS). 1460 Sistema Galego de Saúde (SERGAS), Santiago de Compostela, Spain 1461 ¹⁵³, IIS La Fe, Plataforma de Farmacogenética, Valencia, Spain 1462 ¹⁵⁴, Universidad de Valencia, Departamento de Farmacología, Valencia, Spain 1463 ¹⁵⁵, Data Analysis Department, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz 1464 University Hospital - Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain 1465 ¹⁵⁶. Hospital del Mar, Infectious Diseases Service, Barcelona, Spain 1466 ¹⁵⁷, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain 1467 ¹⁵⁸, CEXS-Universitat Pompeu Fabra, Spanish Network for Research in Infectious Diseases 1468 (REIPI), Barcelona, Spain 1469 ¹⁵⁹, Biocruces Bizkaia Health Research Institute, Basurto University Hospital, Osakidetza, 1470 Bizkaia, Spain 1471 ¹⁶⁰, Sabin Medicina Diagnóstica, Brazil 1472 ¹⁶¹, Opthalmology Department, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz 1473 University Hospital - Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain 1474 ¹⁶², Hospital Sant Joan de Deu, Pediatric Critical Care Unit, Barcelona, Spain 1475

¹⁶³, Paediatric Intensive Care Unit, Agrupación Hospitalaria Clínic-Sant Joan de Déu. 1476 Esplugues de Llobregat, Barcelona, Spain 1477 1478 ¹⁶⁴, Hospital Universitario 12 de Octubre, Department of Immunology, Madrid, Spain ¹⁶⁵, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Transplant 1479 Immunology and Immunodeficiencies Group, Madrid, Spain 1480 ¹⁶⁶, SIGEN Alianza Universidad de los Andes - Fundación Santa Fe de Bogotá, Bogotá, 1481 1482 Colombia ¹⁶⁷, Hospital General de Segovia, Medicina Intensiva, Segovia, Spain 1483 ¹⁶⁸, Programa de Pós-Graduação em Biologia Animal, Universidade de Brasília, Brasília, Brazil 1484 ¹⁶⁹, Clinical Trials Unit, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University 1485 Hospital - Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain 1486 ¹⁷⁰, IMDEA-Food Institute, CEI UAM+CSIC, Madrid, Spain 1487 ¹⁷¹, Intensive Care Unit, Hospital Universitario de Canarias, La Laguna, Spain 1488 ¹⁷², Dirección General de Salud Pública, Consejería de Sanidad, Junta de Castilla y León, 1489 1490 Valladolid, Spain ¹⁷³, Universidade Federal do Rio Grande do Norte, Departamento de Analises Clinicas e 1491 Toxicologicas, Natal, Brazil 1492 ¹⁷⁴, Hospital Universitario La Paz-IDIPAZ, Servicio de Inmunología, Madrid, Spain 1493 ¹⁷⁵, La Paz Institute for Health Research (IdiPAZ), Lymphocyte Pathophysiology in 1494 1495 Immunodeficiencies Group, Madrid, Spain ¹⁷⁶, Hospital Universitario Virgen de las Nieves, Servicio de Enfermedades Infecciosas, 1496 1497 Granada, Spain ¹⁷⁷, Instituto de Investigación Biosanitaria de Granada (ibs GRANADA), Granada, Spain 1498 ¹⁷⁸, Universidad de Granada, Departamento de Medicina, Granada, Spain 1499 ¹⁷⁹, Faculdade de Medicina, Universidade de Brasília, Brazil 1500 ¹⁸⁰, Fundación Jiménez Díaz, Epidemiology, Madrid, Spain 1501 ¹⁸¹, Universidad Autónoma de Madrid, Department of Medicine, Madrid, Spain 1502 ¹⁸², Universidad de Valladolid, Departamento de Medicina, Valladolid, Spain 1503 1504 ¹⁸³, Hospital Universitario Infanta Leonor, Servicio de Medicina Intensiva, Madrid, Spain ¹⁸⁴, Unidad de Genética y Genómica Islas Baleares, Islas Baleares, Spain 1505 ¹⁸⁵, Hospital Universitario Son Espases, Unidad de Diagnóstico Molecular y Genética Clínica, 1506 Islas Baleares, Spain 1507 ¹⁸⁶, Genomics of Complex Diseases Unit, Research Institute of Hospital de la Santa Creu i Sant 1508 Pau, IIB Sant Pau, Barcelona, Spain 1509 ¹⁸⁷, Intensive Care Unit, Hospital Universitario N. S. de Candelaria, Santa Cruz de Tenerife, 1510 1511 Spain ¹⁸⁸, Preventive Medicine Department, Instituto de Investigación Sanitaria-Fundación Jiménez 1512 Díaz University Hospital - Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain 1513 ¹⁸⁹, Servicio de Medicina Interna, Sanatorio Franchin, Buenos Aires, Argentina 1514

1515	¹⁹⁰ , Hospital Universitario del Tajo, Servicio de Medicina Intensiva, Toledo, Spain
1516	¹⁹¹ , Programa de Pós-Graduação em Ciências Médicas, Universidade de Brasília, Brasilia, Brazil
1517 1518	¹⁹² , Programa de Pós-Graduação em Ciências da Saúde, Universidade de Brasília, Brasilia, Brazil
1519 1520	¹⁹³ , Hospital El Bierzo, Gerencia de Asistencia Sanitaria del Bierzo (GASBI), Gerencia Regional de Salud (SACYL), Ponferrada, Spain
1521	¹⁹⁴ , Grupo INVESTEN, Instituto de Salud Carlos III, Madrid, Spain
1522 1523	¹⁹⁵ , Unidad de Cuidados Intensivos, Complejo Universitario de A Coruña (CHUAC), Sistema Galego de Saúde (SERGAS), A Coruña, Spain
1524 1525 1526	 ¹⁹⁶ Programa de Pós-Graduação em Genética da Faculdade de Medicina de Ribeirão Preto ¹⁹⁷ Programa de Pós-Graduação em Química da Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto ¹⁹⁸, Hospital El Bierzo, Unidad Cuidados Intensivos, León, Spain
1527	•
1528	¹⁹⁹ , Spanish National Cancer Research Centre, Familial Cancer Clinical Unit, Madrid, Spain
1529 1530	²⁰⁰ , Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital Clínico San Carlos (HCSC), Madrid, Spain
1531	²⁰¹ , Hospital Universitario Severo Ochoa, Servicio de Medicina Interna, Madrid, Spain
1532	²⁰² , Universidad de Sevilla, Departamento de Enfermería, Seville, Spain
1533	²⁰³ , Hospital General Universitario Gregorio Marañón (IiSGM), Madrid, Spain
1534	²⁰⁴ , Hospital Universitario La Paz-IDIPAZ, Servicio de Pediatría, Madrid, Spain
1535	²⁰⁵ , ERN-ITHACA-European Reference Network
1536 1537	²⁰⁶ , Unidad de Genética y Genómica Islas Baleares, Unidad de Diagnóstico Molecular y Genética Clínica, Hospital Universitario Son Espases, Islas Baleares, Spain
1538	²⁰⁷ , Instituto de Investigación Sanitaria Islas Baleares (IdISBa), Islas Baleares, Spain
1539	²⁰⁸ , Programa de Pós-Graduação em Biologia Animal, Universidade de Brasília, Brasília, Brazil
1540 1541	²⁰⁹ , Programa de Pós-Graduação em Ciências da Saúde, Universidade de Brasília, Brasília, Brazil
1542 1543	²¹⁰ , Programa de Pós-Graduação Profissional em Ensino de Biologia, Universidade de Brasília, Brasília, Brazil
1544	²¹¹ , Programa de Pós-Graduação em Ciências Médicas, Universidade de Brasília, Brasília, Brazil
1545 1546	²¹² , Anatomía Patológica, Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital Clínico San Carlos (HCSC), Madrid, Spain
1547	²¹³ , Tecnológico de Monterrey, Monterrey, Mexico
1548 1549	²¹⁴ , Infectious Diseases, Microbiota and Metabolism Unit, CSIC Associated Unit, Center for Biomedical Research of La Rioja (CIBIR), Logroño, Spain
1550 1551	²¹⁵ , Centro de Investigación en Anomalías Congénitas y Enfermedades Raras (CIACER), Universidad Icesi
1552	²¹⁶ , Departamento de Genetica, Fundación Valle del Lili
1553 1554	²¹⁷ , Universidad Complutense de Madrid, Department of Immunology, Ophthalmology and ENT, Madrid, Spain

1555 1556	²¹⁸ , Department of Neumology, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital - Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
1557	²¹⁹ , Hospital Nuestra Señora de Sonsoles, Ávila, Spain
1558	²²⁰ , Inditex, A Coruña, Spain
1559	²²¹ , Osakidetza, Cruces University Hospital, Barakaldo, Bizkaia, Spain
1560	²²² , GENYCA, Madrid, Spain
1561 1562	²²³ , Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
1563 1564	²²⁴ , Instituto Mexicano del Seguro Social (IMSS), Centro Médico Nacional Siglo XXI, Unidad de Investigación Médica en Enfermedades Infecciosas y Parasitarias, Mexico City, Mexico
1565	²²⁵ , Catalan Institution of Research and Advanced Studies (ICREA), Barcelona, Spain
1566 1567	²²⁶ , Intensive Care Department, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital - Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
1568 1569	²²⁷ , Hospital Universitario Príncipe de Asturias, Servicio de Microbiología Clínica, Madrid, Spain
1570 1571	²²⁸ , Universidad de Alcalá de Henares, Departamento de Biomedicina y Biotecnología, Facultad de Medicina y Ciencias de la Salud, Madrid, Spain
1572 1573	²²⁹ , Drug Research Centre, Institut d'Investigació Biomèdica Sant Pau, IIB-Sant Pau, Barcelona, Spain
1574	²³⁰ , Departamento de Genetica, Clinica imbanaco
1575 1576	 ²³¹, Unidad de Cuidados Intensivos, Hospital Clínico Universitario de Santiago (CHUS), Sistema Galego de Saúde (SERGAS), Santiago de Compostela, Spain
1577	²³² , Universidade de Brasília, Brasilia, Brazil
1578 1579	²³³ , Department of Immunology, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain
1580 1581	²³⁴ , Department of Clinical Sciences, University Fernando Pessoa Canarias, Las Palmas de Gran Canaria, Spain
1582	²³⁵ , University Hospital Germans Trias i Pujol, Pediatrics Department, Badalona, Spain
1583 1584	 ²³⁶, Department of Pathology, Biobank, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital - Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
1585	²³⁷ , Hospital Universitario Virgen de las Nieves, Servicio de Medicina Interna, Granada, Spain
1586 1587	 ²³⁸, Fundación Universitaria de Ciencias de la Salud, Grupo de Ciencias Básicas en Salud (CBS), Bogotá, Colombia
1588	²³⁹ , Sociedad de Cirugía de Bogotá, Hospital de San José, Bogotá, Colombia
1589 1590	²⁴⁰ , Universidad de Granada, Departamento Bioquímica, Biología Molecular e Inmunología III, Granada, Spain
1591	²⁴¹ , Hospital Infanta Elena, Allergy Unit, Valdemoro, Madrid, Spain
1592	²⁴² , Faculty of Medicine, Universidad Francisco de Vitoria, Madrid, Spain
1593	²⁴³ , Hospital Universitario Infanta Leonor, Madrid, Spain

1594	²⁴⁴ , Complutense University of Madrid, Madrid, Spain
1595	²⁴⁵ , Gregorio Marañón Health Research Institute (IiSGM), Madrid, Spain
1596 1597 1598	²⁴⁶ Colégio Militar de Brasília ²⁴⁷ , The John Walton Muscular Dystrophy Research Centre, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
1599 1600	²⁴⁸ , Neuromuscular Unit, Neuropediatrics Department, Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu, Spain
1601	²⁴⁹ , Fundació Docència i Recerca Mutua Terrassa, Terrassa, Spain
1602	²⁵⁰ , Casa de Saúde São Lucas, Natal, Brazil
1603	²⁵¹ , Hospital Rio Grande, Rio Grande do Norte, Natal, Brazil
1604 1605	²⁵² , Universidade Federal do Rio Grande do Norte, Pós-graduação em Biotecnologia - Rede de Biotecnologia do Nordeste (Renorbio), Natal, Brazil
1606 1607	²⁵³ , Intensive Care Unit, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain
1608	²⁵⁴ , Universidad Fernando Pessoa Canarias, Las Palmas de Gran Canaria, Spain
1609	²⁵⁵ , Biobank, Puerta de Hierro-Segovia de Arana Health Research Institute, Madrid, Spain
1610	²⁵⁶ , Universidad Rey Juan Carlos, Madrid, Spain
1611 1612	²⁵⁷ , Reumathology Service, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital - Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
1613 1614	²⁵⁸ , Hospital Clinico Universitario de Valladolid, Servicio de Anestesiologia y Reanimación, Valladolid, Spain
1615 1616	²⁵⁹ , Hospital Clinico Universitario de Valladolid, Servicio de Hematologia y Hemoterapia, Valladolid, Spain
1617	²⁶⁰ , Hospital Universitario Lauro Wanderley, Brazil
1618	²⁶¹ , Hospital Universitario Infanta Leonor, Servicio de Medicina Interna, Madrid, Spain
1619	²⁶² , University Hospital of Burgos, Burgos, Spain
1620	²⁶³ , Universidad de Sevilla, Seville, Spain
1621 1622	²⁶⁴ , Fundación Santa Fe de Bogota, Instituto de servicios medicos de Emergencia y trauma, Bogotá, Colombia
1623	²⁶⁵ , Universidad de los Andes, Bogotá, Colombia
1624	²⁶⁶ , Quironprevención, A Coruña, Spain
1625	²⁶⁷ , Junta de Castilla y León, Consejería de Sanidad, Valladolid, Spain
1626	²⁶⁸ , Gerencia Atención Primaria de Burgos, Burgos, Spain
1627 1628	²⁶⁹ , Immunogenetics-Histocompatibility group, Servicio de Inmunología, Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana, Madrid, Spain
1629	²⁷⁰ , Hospital del Mar, Department of Infectious Diseases, Barcelona, Spain
1630 1631	²⁷¹ , IMIM (Hospital del Mar Medical Research Institute, Institut Hospital del Mar d'Investigacions Mediques), Barcelona, Spain
1632	²⁷² , Universitat Autònoma de Barcelona, Department of Medicine, Spain

- 1633 ²⁷³, Consejería de Sanidad, Comunidad de Madrid, Madrid, Spain
- 1634 ²⁷⁴, Centro para el Desarrollo de la Investigación Científica, Asunción, Paraguay
- 1635 ²⁷⁵, Internal Medicine Department, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz
- 1636 University Hospital Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- 1637 ²⁷⁶, Universidade Federal do Rio Grande do Norte, Programa de Pós Graduação em Nutrição,
 1638 Natal, Brazil
- 1658 Natal, Brazil
- 1639 ²⁷⁷, Preventive Medicine Department, Instituto de Investigacion Sanitaria Galicia Sur, Xerencia
- 1640 de Xestion Integrada de Vigo-Servizo Galego de Saúde, Vigo, Spain
- 1641 ²⁷⁸, Universidade Federal do Rio Grande do Norte, Departamento de Infectologia, Natal, Brazil
- 1642 ²⁷⁹, Hospital de Doenças Infecciosas Giselda Trigueiro, Rio Grande do Norte, Natal, Brazil
- 1643 ²⁸⁰, Genomics Division, Instituto Tecnológico y de Energías Renovables, Santa Cruz de
- 1644 Tenerife, Spain

1645